0001193125-26-327014 | 10-Q | XBRL Viewer | Brightspring Health Services INC

Print Document

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 22.4	$ 23.6	$ 43.1	$ 47.0

- Definition

Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net income	$ 232,819	$ 56,552
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	80,517	84,000
Change in fair value of contingent consideration, net		2,003
Payment of contingent consideration in excess of acquisition date fair value		(1,500)
Provision for credit losses	22,865	40,658
Amortization of deferred debt issuance costs	5,764	5,543
Share-based compensation	23,169	38,483
Deferred income taxes, net	(9,529)	3,892
Gain on sale of discontinued operations	(101,868)
Other	1,014	3,186
Change in operating assets and liabilities, net of acquisitions and dispositions:
Accounts receivable	(152,577)	(112,756)
Prepaid expenses and other current assets	(86,132)	24,411
Inventories	239,989	11,473
Trade accounts payable	(87,503)	53,277
Accrued expenses	27,951	(43,490)
Other assets and liabilities	(29,620)	(15,058)
Net cash provided by operating activities	166,859	150,674
Investing activities:
Purchases of property and equipment	(50,576)	(42,057)
Acquisitions of businesses	(42,203)	(6,754)
Proceeds from sale of discontinued operations	810,908
Other	1,066	1,377
Net cash provided by (used in) investing activities	719,195	(47,434)
Financing activities:
Long-term debt repayments	(320,491)	(23,720)
Repayments of the Revolving Credit Facility, net		(63,300)
Payments of debt issuance costs	(3,378)
Repurchases of shares of common stock	(120,000)
Proceeds from shares issued under share-based compensation plan	32,415	9,062
Taxes paid related to net share settlement of equity awards	(6,607)	(4,512)
Purchase of redeemable noncontrolling interest	(267)	(5,100)
Payments of financing lease obligations	(5,822)	(6,691)
Net cash used in financing activities	(424,150)	(94,261)
Net increase in cash and cash equivalents	461,904	8,979
Cash and cash equivalents at beginning of period	88,477	61,253
Cash and cash equivalents at end of period	550,381	70,232
Cash and cash equivalents included in assets held for sale at end of period		162
Cash and cash equivalents included in continuing operations at end of period	550,381	70,070
Supplemental disclosures of cash flow information:
Interest, net	75,457	96,069
Income taxes, net of refunds	156,704	13,022
Supplemental schedule of non-cash investing and financing activities:
Financing lease obligations assumed	3,783	6,691
Purchases of property and equipment in accounts payable	$ 3,666	$ 4,103

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Net loss excluding allocable redeemable noncontrolling interests	$ (86)	$ (508)	$ (245)	$ (915)

Segment Information - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Reconciliation of income:
Segment depreciation and amortization			$ 80,517	$ 84,000
Expenses not allocated at segment level:
Income from continuing operations, net of income taxes	$ 86,604	$ 8,541	160,887	17,757
Operating Segments
Reconciliation of income:
Total Segment EBITDA	254,910	181,148	489,958	347,954
Segment depreciation and amortization	34,291	34,207	66,573	68,484
Material Reconciling Items
Expenses not allocated at segment level:
Selling, general, and administrative expenses	83,096	90,752	157,601	165,987
Depreciation and amortization	7,132	7,632	13,944	14,187
Interest expense, net	36,879	38,778	75,494	80,541
Income tax expense	$ 6,908	$ 1,238	$ 15,459	$ 998

Debt and Derivatives - Schedule of Total Outstanding Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Total debt	$ 2,249,253	$ 2,569,744
Less: debt issuance costs, net	58,493	62,200
Total debt, net of debt issuance costs	2,190,760	2,507,544
Less: current portion of long-term debt	41,445	52,340
Total long-term debt, net of current portion	$ 2,149,315	$ 2,455,204
First Lien Incremental Term Loan Tranche B-6 - Payable to Lenders at SOFR plus Applicable Margin
Debt Instrument [Line Items]
Rate	5.62%
Total debt	$ 2,214,872
First Lien Incremental Term Loan Tranche B-5 - Payable to Lenders at SOFR plus Applicable Margin
Debt Instrument [Line Items]
Rate		6.22%
Total debt		$ 2,521,255
Revolving Credit Loans - Payable to Lenders at SOFR plus Applicable Margin
Debt Instrument [Line Items]
Rate	5.62%	6.47%
Swingline/Base Rate - Payable to Lenders at ABR plus Applicable Margin
Debt Instrument [Line Items]
Rate	7.75%	8.50%
Amortizing Notes
Debt Instrument [Line Items]
Total debt	$ 19,278	$ 31,360
Notes Payable and Other
Debt Instrument [Line Items]
Total debt	$ 15,103	$ 17,129

Acquisitions

6 Months Ended

Jun. 30, 2026

Business Combination [Abstract]

Acquisitions

4. Acquisitions

2026 Acquisitions

There were no acquisitions completed during the six months ended June 30, 2026.

2025 Acquisitions

During the year ended December 31, 2025, we completed three acquisitions within the Provider Services segment for aggregate consideration net of cash acquired of $247.0 million. We entered into these transactions in order to expand our services and geographic offerings. The operating results of these acquisitions are included in our unaudited condensed consolidated financial statements from the respective dates of the acquisition.

Amedisys and LHC Branches Acquisition

The Company entered into a purchase agreement with Amedisys, Inc., UnitedHealth Group Incorporated and certain of their respective subsidiaries, to purchase certain Amedisys home health and hospice care centers and certain UnitedHealth Group care centers (the “Amedisys and LHC Branches Acquisition”), which is comprised of 110 branches, for a total purchase price of $246.4 million, net of cash acquired. On December 1, 2025 and December 31, 2025, the Company closed on the acquisition of 103 branches and 4 branches, respectively, as a part of the Amedisys and LHC Branches Acquisition for aggregate consideration of $238.5 million net of cash acquired, of which $42.2 million was paid in the first fiscal quarter of 2026. The closing of the remaining three branches is expected to occur in fiscal year 2026, subject to customary regulatory approvals and other closing conditions.

Upon closing, we entered into a one-year TSA with the sellers to support our post-closing operations of the Amedisys and LHC Branches Acquisition. The sellers will continue to provide certain transition services in exchange for fixed-price service fees. Transition services primarily include finance and accounting, human resources, IT, and legal and compliance services. The fees associated with the services rendered under the TSA are not material to our results of operations and are recorded within selling, general, and administrative expenses in our unaudited condensed consolidated statements of operations.

The Amedisys and LHC Branches Acquisition provides home health and hospice care services through several legal entities in 18 states, of which the branches in 17 states have been acquired as of June 30, 2026. Its results are consolidated within the Provider Services reportable segment. The allocation of the purchase price is provisional as of June 30, 2026. Provisional amounts primarily relate to the valuation of intangible assets, certain lease right-of-use assets and lease liabilities, working capital accounts (accounts receivable and certain accruals), and the valuation of redeemable noncontrolling interests. The provisional status is due to pending third‑party valuations, receipt of additional information from the sellers, and completion of certain closing procedures. We expect to complete the purchase price allocation no later than December 1, 2026. During the measurement period, we will record adjustments to provisional amounts with a corresponding adjustment to goodwill, reflecting facts and circumstances that existed as of the acquisition dates. The following table summarizes the consideration paid (in thousands) for the Amedisys and LHC Branches Acquisition and the provisional fair value of the assets acquired and the liabilities assumed at the respective acquisition dates.


Accounts receivable	$	35,456
Prepaid expenses and other current assets		32
Property and equipment		5,633
Goodwill		164,753
Intangible assets		62,897
Operating lease right-of-use assets		12,604
Other assets		88
Trade accounts payable		1,881
Accrued expenses		12,313
Current portion of obligations under operating leases		4,177
Current portion of obligations under financing leases		1,797
Obligations under operating leases, net of current portion		8,427
Obligations under financing leases, net of current portion		3,587
Long-term liabilities		2,773
Redeemable noncontrolling interests		8,084
Noncontrolling interest		(35	)
Aggregate purchase price, net of cash acquired	$	238,459

The Company acquired eight joint ventures as a part of the transaction which are recorded either as redeemable noncontrolling interests or noncontrolling interest on the unaudited condensed consolidated balance sheets based on the nature of the joint venture. During the second fiscal quarter of 2026, the Company purchased the remaining redeemable noncontrolling interest in one of the joint ventures.

The fair value of acquired licenses of $62.9 million was based upon a third-party valuation, of which $56.0 million were assigned an indefinite life. The definite-lived licenses have an estimated weighted average useful life of 10.0 years. We expect all of the goodwill will be deductible for tax purposes. The Company believes the resulting amount of goodwill reflects its expectation of synergistic benefits of the acquisition.

The Amedisys and LHC Branches Acquisition contributed $77.9 million and $156.4 million in revenue during the three and six months ended June 30, 2026, respectively. The Amedisys and LHC Branches Acquisition contributed $6.8 million and $14.2 million

in operating income during the three and six months ended June 30, 2026, respectively. The Amedisys and LHC Branches Acquisition was not completed until the fourth fiscal quarter of 2025; as such it did not contribute any revenue or operating income during the three and six months ended June 30, 2025.

The following table contains the unaudited pro forma consolidated financial information, assuming that the Amedisys and LHC Branches Acquisition transaction closed on January 1, 2025 (in thousands):


	For the Three Months Ended		For the Six Months Ended
	June 30,		June 30,
	2025		2025
Revenue	$	3,236,252	$	6,199,846
Operating income	$	52,101	$	112,825
Net income from continuing operations attributable to BrightSpring Health Services, Inc. and subsidiaries	$	11,795	$	28,832

These pro forma results include adjustments for current factors that would affect the business, including non-recurring transaction costs, depreciation, amortization of acquired intangible assets, and income taxes based on the Company’s statutory tax rate. The unaudited pro forma financial information is not necessarily indicative of either future results of operations or results of operations that might have been achieved had the acquisition been consummated as of January 1, 2025 and does not reflect any operating efficiencies and cost savings that may be realized from the integration of the acquisition.

Others

Aggregate consideration for the two other acquisitions completed in 2025 was approximately $8.5 million. No cash was acquired as a part of these transactions. The operating results of the acquisitions are not material to our results of operations.

The Company expects to finalize the purchase price allocation for the 2025 acquisitions prior to the one-year anniversary date of each acquisition. During the three and six months ended June 30, 2025, the Company incurred $8.3 million and $8.9 million, respectively, of transaction costs related to all 2025 acquisitions, including those acquisitions completed in subsequent quarters of 2025. These costs are included in selling, general, and administrative expenses in our unaudited condensed consolidated statements of operations.

- Definition

The entire disclosure for business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 46
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-46

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 45
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-45

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479326/805-40-45-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-30/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-20/tableOfContent

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-10/tableOfContent

+ Details

Acquisitions (Tables) - Amedisys and LHC Branches Acquisition

6 Months Ended

Jun. 30, 2026

Business Combination [Line Items]

Schedule of Consideration Paid for Acquisitions and Estimated Fair Value of Assets Acquired and Liabilities Assumed

The following table summarizes the consideration paid (in thousands) for the Amedisys and LHC Branches Acquisition and the provisional fair value of the assets acquired and the liabilities assumed at the respective acquisition dates.


Accounts receivable	$	35,456
Prepaid expenses and other current assets		32
Property and equipment		5,633
Goodwill		164,753
Intangible assets		62,897
Operating lease right-of-use assets		12,604
Other assets		88
Trade accounts payable		1,881
Accrued expenses		12,313
Current portion of obligations under operating leases		4,177
Current portion of obligations under financing leases		1,797
Obligations under operating leases, net of current portion		8,427
Obligations under financing leases, net of current portion		3,587
Long-term liabilities		2,773
Redeemable noncontrolling interests		8,084
Noncontrolling interest		(35	)
Aggregate purchase price, net of cash acquired	$	238,459

Schedule of Unaudited Pro Forma Consolidated Financial Information

The following table contains the unaudited pro forma consolidated financial information, assuming that the Amedisys and LHC Branches Acquisition transaction closed on January 1, 2025 (in thousands):


	For the Three Months Ended		For the Six Months Ended
	June 30,		June 30,
	2025		2025
Revenue	$	3,236,252	$	6,199,846
Operating income	$	52,101	$	112,825
Net income from continuing operations attributable to BrightSpring Health Services, Inc. and subsidiaries	$	11,795	$	28,832

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-47

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

+ Details

Earnings Per Share ("EPS") (Tables)

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

Summary of Basic and Diluted Net Income Per Share

The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common shareholders (in thousands, except per share amounts):


	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2026			2025			2026			2025
Numerator:
Net income from continuing operations	$	86,604		$	8,541		$	160,887		$	17,757
Less: Net loss attributable to noncontrolling interests		(81	)		(666	)		(238	)		(1,198	)
Net income from continuing operations attributable to common shareholders		86,685			9,207			161,125			18,955
Net (loss) income from discontinued operations		(2,395	)		19,001			71,932			38,795
Net income attributable to common shareholders	$	84,290		$	28,208		$	233,057		$	57,750

Denominator:
Weighted-average shares outstanding - basic		206,042			201,807			205,381			200,516

Effect of dilutive securities:
Stock options		8,947			8,098			9,468			8,167
RSUs		5,287			6,431			6,342			6,280
TEUs		—			—			—			—
Weighted-average shares outstanding - diluted		220,276			216,336			221,191			214,963

Basic income (loss) per share attributable to common shareholders:
Continuing operations	$	0.42		$	0.05		$	0.78		$	0.09
Discontinued operations	$	(0.01	)	$	0.09		$	0.35		$	0.20
Net income per share	$	0.41		$	0.14		$	1.13		$	0.29

Diluted income (loss) per share attributable to common shareholders:
Continuing operations	$	0.39		$	0.04		$	0.73		$	0.09
Discontinued operations	$	(0.01	)	$	0.09		$	0.32		$	0.18
Net income per share	$	0.38		$	0.13		$	1.05		$	0.27

Acquisitions - Schedule of Unaudited Pro Forma Consolidated Financial Information (Details) - Amedisys and LHC Branches Acquisition - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Business Combination, Pro Forma Information [Line Items]
Revenue	$ 77,900	$ 3,236,252	$ 156,400	$ 6,199,846
Operating income	$ 6,800	52,101	$ 14,200	112,825
Net income from continuing operations attributable to BrightSpring Health Services, Inc. and subsidiaries		$ 11,795		$ 28,832

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Discontinued Operations - Summary of the Financial Results of the Community Living Business (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Disposal Group, Including Discontinued Operations [Line Items]
(Loss) income from discontinued operations, net of income taxes	$ (2,395)	$ 19,001	$ 71,932	$ 38,795
Community Living Business \| Discontinued Operations
Disposal Group, Including Discontinued Operations [Line Items]
Services revenue	0	307,683	306,646	606,789
Cost of services	0	211,614	206,585	415,797
Gross profit	0	96,069	100,061	190,992
Selling, general, and administrative expenses	7,703	63,739	45,669	124,483
Operating (loss) income of discontinued operations	(7,703)	32,330	54,392	66,509
Interest expense, net	0	7,590	6,677	15,497
(Loss) gain on sale of discontinued operations	(1,544)	0	101,868	0
(Loss) income of discontinued operations before incomes taxes	(9,247)	24,740	149,583	51,012
Income tax (benefit) expense of discontinued operations	(6,852)	5,739	77,651	12,217
(Loss) income from discontinued operations, net of income taxes	$ (2,395)	$ 19,001	$ 71,932	$ 38,795

Revenue - Schedule of Revenue by Payor Type (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Disaggregation of Revenue [Line Items]
Revenue	$ 3,873,140	$ 3,147,698	$ 7,486,861	$ 6,025,827
Commercial Insurance
Disaggregation of Revenue [Line Items]
Revenue	1,112,500	786,100	2,126,800	1,502,000
Medicaid
Disaggregation of Revenue [Line Items]
Revenue	436,600	354,700	842,300	678,000
Medicare Part A
Disaggregation of Revenue [Line Items]
Revenue	309,800	264,700	618,700	527,500
Medicare Part B
Disaggregation of Revenue [Line Items]
Revenue	30,600	20,100	52,400	41,100
Medicare Part C
Disaggregation of Revenue [Line Items]
Revenue	720,500	590,200	1,387,500	1,110,500
Medicare Part D
Disaggregation of Revenue [Line Items]
Revenue	1,149,900	1,008,400	2,224,000	1,919,300
Private and Other
Disaggregation of Revenue [Line Items]
Revenue	113,200	123,500	235,200	247,400
Pharmacy Solutions
Disaggregation of Revenue [Line Items]
Revenue	3,407,100	2,790,100	6,578,500	5,322,300
Pharmacy Solutions \| Commercial Insurance
Disaggregation of Revenue [Line Items]
Revenue	1,053,500	742,000	2,012,900	1,416,500
Pharmacy Solutions \| Medicaid
Disaggregation of Revenue [Line Items]
Revenue	339,300	266,200	647,900	504,400
Pharmacy Solutions \| Medicare Part A
Disaggregation of Revenue [Line Items]
Revenue	136,300	138,900	274,000	279,300
Pharmacy Solutions \| Medicare Part B
Disaggregation of Revenue [Line Items]
Revenue	18,300	18,700	38,600	38,200
Pharmacy Solutions \| Medicare Part C
Disaggregation of Revenue [Line Items]
Revenue	653,700	555,600	1,256,100	1,043,300
Pharmacy Solutions \| Medicare Part D
Disaggregation of Revenue [Line Items]
Revenue	1,149,900	1,008,400	2,224,000	1,919,300
Pharmacy Solutions \| Private and Other
Disaggregation of Revenue [Line Items]
Revenue	56,100	60,300	125,000	121,300
Provider Services
Disaggregation of Revenue [Line Items]
Revenue	466,000	357,600	908,400	703,500
Provider Services \| Commercial Insurance
Disaggregation of Revenue [Line Items]
Revenue	59,000	44,100	113,900	85,500
Provider Services \| Medicaid
Disaggregation of Revenue [Line Items]
Revenue	97,300	88,500	194,400	173,600
Provider Services \| Medicare Part A
Disaggregation of Revenue [Line Items]
Revenue	173,500	125,800	344,700	248,200
Provider Services \| Medicare Part B
Disaggregation of Revenue [Line Items]
Revenue	12,300	1,400	13,800	2,900
Provider Services \| Medicare Part C
Disaggregation of Revenue [Line Items]
Revenue	66,800	34,600	131,400	67,200
Provider Services \| Private and Other
Disaggregation of Revenue [Line Items]
Revenue	$ 57,100	$ 63,200	$ 110,200	$ 126,100
Product Concentration Risk \| Revenue
Disaggregation of Revenue [Line Items]
% of Revenue	100.00%	100.00%	100.00%	100.00%
Product Concentration Risk \| Revenue \| Commercial Insurance
Disaggregation of Revenue [Line Items]
% of Revenue	28.70%	25.00%	28.40%	24.90%
Product Concentration Risk \| Revenue \| Medicaid
Disaggregation of Revenue [Line Items]
% of Revenue	11.30%	11.30%	11.30%	11.30%
Product Concentration Risk \| Revenue \| Medicare Part A
Disaggregation of Revenue [Line Items]
% of Revenue	8.00%	8.40%	8.30%	8.70%
Product Concentration Risk \| Revenue \| Medicare Part B
Disaggregation of Revenue [Line Items]
% of Revenue	0.80%	0.60%	0.70%	0.60%
Product Concentration Risk \| Revenue \| Medicare Part C
Disaggregation of Revenue [Line Items]
% of Revenue	18.60%	18.80%	18.60%	18.40%
Product Concentration Risk \| Revenue \| Medicare Part D
Disaggregation of Revenue [Line Items]
% of Revenue	29.70%	32.00%	29.70%	31.90%
Product Concentration Risk \| Revenue \| Private and Other
Disaggregation of Revenue [Line Items]
% of Revenue	2.90%	3.90%	3.00%	4.20%
Product Concentration Risk \| Revenue \| Pharmacy Solutions
Disaggregation of Revenue [Line Items]
% of Revenue	88.00%	88.60%	87.90%	88.30%
Product Concentration Risk \| Revenue \| Pharmacy Solutions \| Commercial Insurance
Disaggregation of Revenue [Line Items]
% of Revenue	27.20%	23.60%	26.90%	23.50%
Product Concentration Risk \| Revenue \| Pharmacy Solutions \| Medicaid
Disaggregation of Revenue [Line Items]
% of Revenue	8.80%	8.50%	8.70%	8.40%
Product Concentration Risk \| Revenue \| Pharmacy Solutions \| Medicare Part A
Disaggregation of Revenue [Line Items]
% of Revenue	3.50%	4.40%	3.70%	4.60%
Product Concentration Risk \| Revenue \| Pharmacy Solutions \| Medicare Part B
Disaggregation of Revenue [Line Items]
% of Revenue	0.50%	0.60%	0.50%	0.60%
Product Concentration Risk \| Revenue \| Pharmacy Solutions \| Medicare Part C
Disaggregation of Revenue [Line Items]
% of Revenue	16.90%	17.70%	16.80%	17.30%
Product Concentration Risk \| Revenue \| Pharmacy Solutions \| Medicare Part D
Disaggregation of Revenue [Line Items]
% of Revenue	29.70%	32.00%	29.70%	31.90%
Product Concentration Risk \| Revenue \| Pharmacy Solutions \| Private and Other
Disaggregation of Revenue [Line Items]
% of Revenue	1.40%	1.80%	1.60%	2.00%
Product Concentration Risk \| Revenue \| Provider Services
Disaggregation of Revenue [Line Items]
% of Revenue	12.00%	11.40%	12.10%	11.70%
Product Concentration Risk \| Revenue \| Provider Services \| Commercial Insurance
Disaggregation of Revenue [Line Items]
% of Revenue	1.50%	1.40%	1.50%	1.40%
Product Concentration Risk \| Revenue \| Provider Services \| Medicaid
Disaggregation of Revenue [Line Items]
% of Revenue	2.50%	2.80%	2.60%	2.90%
Product Concentration Risk \| Revenue \| Provider Services \| Medicare Part A
Disaggregation of Revenue [Line Items]
% of Revenue	4.50%	4.00%	4.60%	4.10%
Product Concentration Risk \| Revenue \| Provider Services \| Medicare Part B
Disaggregation of Revenue [Line Items]
% of Revenue	0.30%	0.00%	0.20%	0.00%
Product Concentration Risk \| Revenue \| Provider Services \| Medicare Part C
Disaggregation of Revenue [Line Items]
% of Revenue	1.70%	1.10%	1.80%	1.10%
Product Concentration Risk \| Revenue \| Provider Services \| Private and Other
Disaggregation of Revenue [Line Items]
% of Revenue	1.50%	2.10%	1.40%	2.20%

Discontinued Operations - Summary of the Aggregate Carrying Amounts of Assets and Liabilities Held for Sale (Parenthetical) (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Community Living Business \| Discontinued Operations
Disposal Group, Including Discontinued Operations [Line Items]
Accumulated depreciation	$ 104,314

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482130/360-10-45-14

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482130/360-10-45-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 102
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483474/205-20-55-102

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-10

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.Z.5.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480781/205-20-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480868/205-20-S45-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Subparagraph (d)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480837/205-20-S50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

+ Details

Discontinued Operations - Summary of the Aggregate Carrying Amounts of Assets and Liabilities Held for Sale (Details) - Community Living Business - Discontinued Operations $ in Thousands	Dec. 31, 2025 USD ($)
Current assets:
Cash and cash equivalents	$ 107
Accounts receivable, net of allowance for credit losses	136,875
Inventories	3,294
Prepaid expenses and other current assets	2,717
Total current assets held for sale	142,993
Property and equipment, net of accumulated depreciation of $104,314	83,465
Goodwill	307,640
Intangible assets, net of accumulated amortization	216,192
Operating lease right-of-use assets, net	129,005
Other assets	2,894
Total assets held for sale	882,189
Current liabilities:
Trade accounts payable	25,081
Accrued expenses	59,038
Current portion of obligations under operating leases	32,749
Current portion of obligations under financing leases	7,691
Total current liabilities held for sale	124,559
Obligations under operating leases, net of current portion	57,771
Obligations under financing leases, net of current portion	12,766
Deferred income taxes, net	390
Long-term liabilities	508
Total liabilities held for sale	$ 195,994

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Security Trading Plans of Directors and Executive Officers On June 16, 2026, Scott Greenwell, Executive Vice President and President, PharMerica, entered into a stock trading plan designed to comply with Rule 10b5-1 under the Exchange Act (the “Rule 10b5-1 Plan”). The Rule 10b5-1 Plan provides for the sale, subject to certain price limits, of up to 11,973 shares of the Company’s common stock. The Rule 10b5-1 Plan has a trading effective date of September 14, 2026, and no sales are permitted to occur before this date. The Rule 10b5-1 Plan will terminate on September 14, 2026, unless terminated earlier pursuant to the terms of the Rule 10b5-1 Plan. If all shares are sold pursuant to the Rule 10b5-1 Plan, Mr. Greenwell will continue to satisfy the Company’s stock ownership guidelines.
Scott Greenwell [Member]
Trading Arrangements, by Individual
Name	Scott Greenwell
Title	Executive Vice President and President
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 16, 2026
Rule 10b5-1 Arrangement Terminated	true
Termination Date	September 14, 2026
Expiration Date	September 14, 2026
Arrangement Duration	91 days
Aggregate Available	11,973

Significant Accounting Policies - Additional Information (Details) - shares	Jun. 30, 2026	Mar. 31, 2026
March 2026 Offering
Summary Of Significant Accounting Policy [Line Items]
Common stock shares purchased from underwriter		1,464,807
June 2026 Offering
Summary Of Significant Accounting Policy [Line Items]
Common stock shares purchased from underwriter	1,026,465
Common Stock \| March 2026 Offering
Summary Of Significant Accounting Policy [Line Items]
Shares issued		20,000,000
Common Stock \| June 2026 Offering
Summary Of Significant Accounting Policy [Line Items]
Shares issued	14,999,771

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Acquisitions - Additional Information (Details) $ in Thousands			1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Dec. 31, 2025 Branch	Dec. 01, 2025 Branch	Dec. 31, 2025 USD ($) Branch	Jun. 30, 2026 USD ($)	Mar. 31, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) Acquisitions	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($) Acquisitions Branch
2025 Acquisitions
Business Combination [Line Items]
Number of businesses acquired \| Acquisitions									2
Consideration transferred to asset acquired									$ 8,500
Cash acquired from acquisition									$ 0
Transaction costs						$ 8,300		$ 8,900
2025 Acquisitions \| Provider Services
Business Combination [Line Items]
Number of businesses acquired \| Acquisitions									3
Consideration transferred to asset acquired									$ 247,000
2026 Acquisitions
Business Combination [Line Items]
Number of businesses acquired \| Acquisitions							0
Amedisys and LHC Branches Acquisition
Business Combination [Line Items]
Consideration transferred to asset acquired			$ 238,459		$ 42,200				$ 246,400
Number of branches \| Branch									110
Number of branches acquired \| Branch	4	103
Number of branches to be acquired \| Branch			3
Definite-lived intangible assets estimated weighted average useful life							10 years
Proforma revenue				$ 77,900		3,236,252	$ 156,400	6,199,846
Operating income				$ 6,800		$ 52,101	14,200	$ 112,825
Amedisys and LHC Branches Acquisition \| Indefinite-lived Licenses
Business Combination [Line Items]
Intangible assets							56,000
Amedisys and LHC Branches Acquisition \| Definite-lived Licenses
Business Combination [Line Items]
Intangible assets							$ 62,900

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Schedule Of Intangible Assets [Line Items]
Definite-lived assets, Gross	$ 905,472	$ 911,567
Definite-lived assets, Accumulated Amortization	582,573	547,262
Total intangible assets, Net Carrying Value	322,899	364,305
Total intangible assets, Gross	1,096,997	1,104,817
Total intangible assets, Net Carrying Value	514,424	557,555
Licenses
Schedule Of Intangible Assets [Line Items]
Indefinite-lived assets	191,525	193,250
Customer Relationships
Schedule Of Intangible Assets [Line Items]
Definite-lived assets, Gross	501,510	502,160
Definite-lived assets, Accumulated Amortization	381,851	356,146
Total intangible assets, Net Carrying Value	$ 119,659	146,014
Customer Relationships \| Minimum
Schedule Of Intangible Assets [Line Items]
Life (years)	5 years
Customer Relationships \| Maximum
Schedule Of Intangible Assets [Line Items]
Life (years)	20 years
Trade Names
Schedule Of Intangible Assets [Line Items]
Definite-lived assets, Gross	$ 318,768	318,768
Definite-lived assets, Accumulated Amortization	165,644	154,601
Total intangible assets, Net Carrying Value	$ 153,124	164,167
Trade Names \| Minimum
Schedule Of Intangible Assets [Line Items]
Life (years)	2 years
Trade Names \| Maximum
Schedule Of Intangible Assets [Line Items]
Life (years)	20 years
Licenses
Schedule Of Intangible Assets [Line Items]
Definite-lived assets, Gross	$ 67,120	67,395
Definite-lived assets, Accumulated Amortization	21,011	18,886
Total intangible assets, Net Carrying Value	$ 46,109	48,509
Licenses \| Minimum
Schedule Of Intangible Assets [Line Items]
Life (years)	10 years
Licenses \| Maximum
Schedule Of Intangible Assets [Line Items]
Life (years)	20 years
Doctor/Payor Network
Schedule Of Intangible Assets [Line Items]
Definite-lived assets, Gross	$ 3,300	5,650
Definite-lived assets, Accumulated Amortization	2,922	4,987
Total intangible assets, Net Carrying Value	$ 378	663
Doctor/Payor Network \| Minimum
Schedule Of Intangible Assets [Line Items]
Life (years)	5 years
Doctor/Payor Network \| Maximum
Schedule Of Intangible Assets [Line Items]
Life (years)	8 years
Covenants Not to Complete
Schedule Of Intangible Assets [Line Items]
Definite-lived assets, Gross	$ 3,834	6,654
Definite-lived assets, Accumulated Amortization	2,438	4,717
Total intangible assets, Net Carrying Value	$ 1,396	1,937
Covenants Not to Complete \| Minimum
Schedule Of Intangible Assets [Line Items]
Life (years)	2 years
Covenants Not to Complete \| Maximum
Schedule Of Intangible Assets [Line Items]
Life (years)	7 years
Other Intangible Assets [Member]
Schedule Of Intangible Assets [Line Items]
Definite-lived assets, Gross	$ 10,940	10,940
Definite-lived assets, Accumulated Amortization	8,707	7,925
Total intangible assets, Net Carrying Value	$ 2,233	$ 3,015
Other Intangible Assets [Member] \| Minimum
Schedule Of Intangible Assets [Line Items]
Life (years)	5 years
Other Intangible Assets [Member] \| Maximum
Schedule Of Intangible Assets [Line Items]
Life (years)	7 years

Detail of Certain Balance Sheet Accounts (Tables)

6 Months Ended

Jun. 30, 2026

Disclosure Text Block Supplement [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	June 30, 2026		December 31, 2025
Non-trade receivables	$	61,709	$	38,196
Income tax receivable		49,050		864
Rebate receivable		45,393		32,407
Inventory returns receivable		11,594		11,019
Dues and subscriptions		11,573		7,588
Prepaid insurance		5,440		13,255
Other prepaid expenses and current assets		20,404		15,263
Total prepaid expenses and other current assets	$	205,163	$	118,592

Schedule of Other Assets

Other assets consist of the following (in thousands):


	June 30, 2026		December 31, 2025
Insurance recoveries	$	40,760	$	7,251
Interest rate swaps		14,167		1,181
Other investments		7,544		7,481
Cloud computing		6,863		6,017
Deposits		5,816		5,722
Deferred compensation		5,022		4,702
Notes receivable		1,940		4,012
Other assets		3,122		3,346
Total other assets	$	85,234	$	39,712

Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):


	June 30, 2026		December 31, 2025
Wages and payroll taxes	$	153,232	$	131,162
Compensated absences		35,152		31,543
Health insurance reserves		28,011		15,389
Workers compensation insurance reserves		19,992		24,897
Legal settlements and professional fees		18,569		10,525
Checks in excess of cash balance		17,731		34,824
General and professional liability insurance reserves		16,376		7,696
Deferred revenue		13,083		9,039
Property insurance reserves		8,085		11,170
Automobile insurance reserves		6,529		5,585
Taxes other than income taxes		4,243		3,506
Other		50,698		47,688
Total accrued expenses	$	371,701	$	333,024

Schedule of Long-Term Liabilities

Long-term liabilities consist of the following (in thousands):


	June 30, 2026		December 31, 2025
General and professional liability insurance reserves	$	37,219	$	25,032
Workers compensation insurance reserves		24,591		25,369
Automobile insurance reserves		7,795		9,849
Deferred compensation		5,022		4,702
Other		1,985		1,613
Total long-term liabilities	$	76,612	$	66,565

Segment Information - Schedule of Reportable Segments Reconcile of Segment Information (Details) - Operating Segments - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Segment Reporting [Line Items]
Cost of drugs	$ 2,916,899	$ 2,377,477	$ 5,589,692	$ 4,525,053
Cost of services	271,402	216,444	532,326	427,989
Other direct costs	192,093	178,925	389,875	359,564
Segment selling, general, and administrative expenses	272,127	227,911	551,583	433,751
Segment depreciation and amortization expense	34,291	34,207	66,573	68,484
Segment EBITDA	254,910	181,148	489,958	347,954
Products
Segment Reporting [Line Items]
Revenues	3,407,173	2,790,101	6,578,522	5,322,272
Services
Segment Reporting [Line Items]
Revenues	465,967	357,597	908,339	703,555
Pharmacy Solutions
Segment Reporting [Line Items]
Cost of drugs	2,916,899	2,377,477	5,589,692	4,525,053
Other direct costs	192,093	178,925	389,875	359,564
Segment selling, general, and administrative expenses	143,612	136,040	300,646	251,778
Segment depreciation and amortization expense	25,480	27,033	50,808	54,541
Segment EBITDA	180,049	124,692	349,117	240,418
Pharmacy Solutions \| Products
Segment Reporting [Line Items]
Revenues	3,407,173	2,790,101	6,578,522	5,322,272
Provider Services
Segment Reporting [Line Items]
Cost of services	271,402	216,444	532,326	427,989
Segment selling, general, and administrative expenses	128,515	91,871	250,937	181,973
Segment depreciation and amortization expense	8,811	7,174	15,765	13,943
Segment EBITDA	74,861	56,456	140,841	107,536
Provider Services \| Services
Segment Reporting [Line Items]
Revenues	$ 465,967	$ 357,597	$ 908,339	$ 703,555

Revenue (Tables)

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

Schedule of Revenue by Payor Type

The following tables set forth revenue by payor type (in millions):


	Pharmacy Solutions
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
	2026					2025					2026					2025
	Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue
Commercial insurance	$	1,053.5		27.2	%	$	742.0		23.6	%	$	2,012.9		26.9	%	$	1,416.5		23.5	%
Medicaid		339.3		8.8	%		266.2		8.5	%		647.9		8.7	%		504.4		8.4	%
Medicare Part A		136.3		3.5	%		138.9		4.4	%		274.0		3.7	%		279.3		4.6	%
Medicare Part B		18.3		0.5	%		18.7		0.6	%		38.6		0.5	%		38.2		0.6	%
Medicare Part C		653.7		16.9	%		555.6		17.7	%		1,256.1		16.8	%		1,043.3		17.3	%
Medicare Part D		1,149.9		29.7	%		1,008.4		32.0	%		2,224.0		29.7	%		1,919.3		31.9	%
Private & other		56.1		1.4	%		60.3		1.8	%		125.0		1.6	%		121.3		2.0	%
	$	3,407.1		88.0	%	$	2,790.1		88.6	%	$	6,578.5		87.9	%	$	5,322.3		88.3	%


	Provider Services
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
	2026					2025					2026					2025
	Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue
Commercial insurance	$	59.0		1.5	%	$	44.1		1.4	%	$	113.9		1.5	%	$	85.5		1.4	%
Medicaid		97.3		2.5	%		88.5		2.8	%		194.4		2.6	%		173.6		2.9	%
Medicare Part A		173.5		4.5	%		125.8		4.0	%		344.7		4.6	%		248.2		4.1	%
Medicare Part B		12.3		0.3	%		1.4		0.0	%		13.8		0.2	%		2.9		0.0	%
Medicare Part C		66.8		1.7	%		34.6		1.1	%		131.4		1.8	%		67.2		1.1	%
Private & other		57.1		1.5	%		63.2		2.1	%		110.2		1.4	%		126.1		2.2	%
	$	466.0		12.0	%	$	357.6		11.4	%	$	908.4		12.1	%	$	703.5		11.7	%


	Consolidated
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
	2026					2025					2026					2025
	Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue
Commercial insurance	$	1,112.5		28.7	%	$	786.1		25.0	%	$	2,126.8		28.4	%	$	1,502.0		24.9	%
Medicaid		436.6		11.3	%		354.7		11.3	%		842.3		11.3	%		678.0		11.3	%
Medicare Part A		309.8		8.0	%		264.7		8.4	%		618.7		8.3	%		527.5		8.7	%
Medicare Part B		30.6		0.8	%		20.1		0.6	%		52.4		0.7	%		41.1		0.6	%
Medicare Part C		720.5		18.6	%		590.2		18.8	%		1,387.5		18.6	%		1,110.5		18.4	%
Medicare Part D		1,149.9		29.7	%		1,008.4		32.0	%		2,224.0		29.7	%		1,919.3		31.9	%
Private & other		113.2		2.9	%		123.5		3.9	%		235.2		3.0	%		247.4		4.2	%
	$	3,873.1		100.0	%	$	3,147.7		100.0	%	$	7,486.9		100.0	%	$	6,025.8		100.0	%

Revenue - Additional Information (Details)	6 Months Ended
Revenue - Additional Information (Details)	Jun. 30, 2026 Customer
Customer Concentration Risk \| Revenue
Product Information [Line Items]
Number of customer whose revenue was 10% or more of consolidated revenue	0

Debt and Derivatives - Additional Information (Details) - USD ($)					3 Months Ended		6 Months Ended
	May 28, 2026	Dec. 11, 2024	Feb. 21, 2024	Mar. 05, 2019	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Debt Instrument [Line Items]
Repayment of borrowings							$ 320,491,000	$ 23,720,000
Fair value of interest rate swaps asset					$ 14,300,000		14,300,000
Fair value of interest rate swaps liability									$ 400,000
Interest received					400,000	$ 4,400,000	1,000,000	$ 8,800,000
Pre-tax gains							$ 6,500,000
Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, maturity date			Jun. 30, 2028
Debt instrument, floor rate	0.00%						0.00%
Line of credit facility, maximum borrowing capacity					475,000,000		$ 475,000,000
Borrowings outstanding					475,000,000		$ 475,000,000		475,000,000
Revolving Credit Facility \| SOFR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	2.00%						2.75%
Letter of Credit
Debt Instrument [Line Items]
Borrowings outstanding					0		$ 0		0
LC Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity					65,000,000		65,000,000
Line of credit facility, remaining borrowing capacity					1,100,000		1,100,000		2,200,000
Letter of credit outstanding amount					$ 63,900,000		63,900,000		$ 62,800,000
First Lien Credit Agreement
Debt Instrument [Line Items]
Line of credit facility, agreement date				Mar. 05, 2019
First Lien Credit Agreement \| ABR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	1.00%
First Lien Credit Agreement \| Tranche B- 5 Term Loan
Debt Instrument [Line Items]
Principal amount		$ 2,553,200,000
Line of credit facility, maturity date		Feb. 21, 2031
Principal at issuance (as a percent)		0.25%
First Lien Credit Agreement \| Tranche B- 5 Term Loan \| SOFR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		2.50%
First Lien Credit Agreement \| Tranche B- 5 Term Loan \| ABR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.50%
First Lien Credit Agreement \| Tranche B-6 Term Loan
Debt Instrument [Line Items]
Principal amount	$ 2,214,900,000
Repayment of borrowings	$ 300,000,000
Line of credit facility, maturity date	Feb. 21, 2031
Principal at issuance (as a percent)	0.25%
First Lien Credit Agreement \| Tranche B-6 Term Loan \| SOFR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	2.00%
Swingline Loans \| Revolving Credit Facility
Debt Instrument [Line Items]
Aggregate amount of outstanding							$ 50,000,000
Swingline Loans \| Revolving Credit Facility \| ABR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	1.00%						1.75%
Debt instrument, floor rate	0.00%						0.00%
LC Sublimit \| Revolving Credit Facility
Debt Instrument [Line Items]
Aggregate amount of outstanding							$ 82,500,000

Tangible Equity Units ("TEUs")

6 Months Ended

Jun. 30, 2026

Equity [Abstract]

Tangible Equity Units ("TEUs")

7. Tangible Equity Units (“TEUs”)

Concurrently with the IPO in 2024, we issued 8,000,000 TEUs, which have a stated amount of $50.00 per unit. Each TEU is comprised of a prepaid stock purchase contract (“Purchase Contract”) and a senior amortizing note (“Amortizing Note”) due February 1, 2027, each issued by the Company. Each TEU may be separated by a holder into its constituent Purchase Contract and Amortizing Note, each of which is considered a freestanding financial instrument. The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU.

The value allocated to the Purchase Contract is reflected net of issuance costs in additional paid-in capital. The value allocated to the Amortizing Notes is reflected in long-term debt, with payments expected in the next twelve months reflected in current portion of long-term debt, in the unaudited condensed consolidated balance sheets. The long-term portion of the Amortizing Notes as of December 31, 2025 was $6.6 million. Because the final installment payment date of February 1, 2027 is within one year of June 30, 2026, the entire carrying amount of the Amortizing Notes was classified within current portion of long-term debt as of June 30, 2026. The current portion of the Amortizing Notes as of June 30, 2026 and December 31, 2025 was $19.3 million and $24.8 million, respectively. Issuance costs related to the Amortizing Notes are reflected as a reduction of the carrying amount and are amortized through the maturity date using the effective interest rate method.

Amortizing Notes

The Company pays equal quarterly cash installments of $0.8438 per Amortizing Note on February 1, May 1, August 1 and November 1, commencing on May 1, 2024, except for the May 1, 2024 installment payment, which was $0.8531 per Amortizing Note, with a final installment payment date of February 1, 2027. In the aggregate, the annual quarterly cash installments are the equivalent of 6.75% per year. Each installment payment constitutes a payment of interest and a partial repayment of principal. The Company paid $6.7 million and $13.5 million in TEU installment payments during the three and six months ended June 30, 2026, respectively, as compared to $6.7 million and $13.5 million during the three and six months ended June 30, 2025, respectively. The Amortizing Notes rank equally in right of payment with all other existing and future unsecured senior indebtedness and rank senior to all of our existing and future indebtedness, if any, that is subordinated to the Amortizing Notes.

Purchase Contracts

At any time prior to the second scheduled trading day immediately preceding February 1, 2027, a holder may elect to settle its Purchase Contract early, in whole or in part, at an early settlement rate equal to the minimum settlement rate. The Company has the right to settle the Purchase Contracts on or after November 1, 2024, in whole but not in part, on a date fixed by it at an early mandatory settlement rate equal to the maximum settlement rate, subject to certain exceptions. During the three and six months ended June 30, 2026, 2,526,146 TEUs were converted at the holder’s option. During the three and six months ended June 30, 2025, no TEUs were converted at the holder’s option.

Unless settled earlier at the holder’s option or at the Company’s election, each Purchase Contract will, subject to postponement in certain limited circumstances, automatically settle on February 1, 2027 for a number of shares of our common stock, subject to certain anti-dilution adjustments, based upon the 20-day volume-weighted average price of our common stock.

The Purchase Contracts are mandatorily convertible into a minimum of 26.2 million shares or a maximum of 30.8 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 26.2 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding to the extent that the average applicable market value is equal to or greater than $13.00 but is less than or equal to $15.28 during the period (see Note 10).

Goodwill and Intangible Assets - Summary of Changes to Goodwill, by Reportable Segment (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2026 USD ($)
Goodwill [Line Items]
Goodwill, Beginning balance	$ 2,545,673
Measurement period adjustments	(10,289)
Foreign currency adjustments	(140)
Goodwill, Ending balance	2,535,244
Pharmacy Solutions
Goodwill [Line Items]
Goodwill, Beginning balance	841,052
Measurement period adjustments	0
Foreign currency adjustments	0
Goodwill, Ending balance	841,052
Provider Services
Goodwill [Line Items]
Goodwill, Beginning balance	1,704,621
Measurement period adjustments	(10,289)
Foreign currency adjustments	(140)
Goodwill, Ending balance	$ 1,694,192

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Earnings Per Share ("EPS") - Additional Information (Details) - $ / shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2026	Jun. 30, 2025
Earnings per Share [Line Items]
Potentially dilutive common share equivalents excluded from the computation of diluted net income (loss) per share	0	0
Minimum
Earnings per Share [Line Items]
Average applicable market value	$ 13	$ 13
Minimum \| TEUs
Earnings per Share [Line Items]
Average applicable market value	$ 15.28	$ 15.28	$ 15.28

Income Taxes - Schedule of Reconciliation of Effective Tax Rate (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Tax Disclosure [Abstract]
Estimated annual effective tax rate before discrete items	25.40%	27.10%	25.40%	26.40%
Discrete items recognized	(18.00%)	(14.40%)	(16.60%)	(21.10%)
Effective tax rate recognized in the statements of operations	7.40%	12.70%	8.80%	5.30%

Detail of Certain Balance Sheet Accounts - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Disclosure Text Block Supplement [Abstract]
Wages and payroll taxes	$ 153,232	$ 131,162
Compensated absences	35,152	31,543
Health insurance reserves	28,011	15,389
Workers compensation insurance reserves	19,992	24,897
Legal settlements and professional fees	18,569	10,525
Checks in excess of cash balance	17,731	34,824
General and professional liability insurance reserves	16,376	7,696
Deferred revenue	13,083	9,039
Property insurance reserves	8,085	11,170
Automobile insurance reserves	6,529	5,585
Taxes other than income taxes	4,243	3,506
Other	50,698	47,688
Total accrued expenses	$ 371,701	$ 333,024

Debt and Derivatives - Schedule of Interest Rate Swap with Notional Value (Parenthetical) (Details) $ in Millions	Dec. 31, 2025 USD ($)
Debt Disclosure [Abstract]
Notional amount, to hedge cash flow risk of variability	$ 500

Debt and Derivatives

6 Months Ended

Jun. 30, 2026

Debt Disclosure [Abstract]

Debt and Derivatives

6. Debt and Derivatives

The table below summarizes the total outstanding debt of the Company (in thousands):


	June 30, 2026					December 31, 2025
	Rate			Amount		Rate			Amount
First Lien Incremental Term Loan Tranche B-6 - payable to lenders at SOFR plus applicable margin		5.62	%	$	2,214,872		—		$	—
First Lien Incremental Term Loan Tranche B-5 - payable to lenders at SOFR plus applicable margin		—			—		6.22	%		2,521,255
Revolving Credit Loans - payable to lenders at SOFR plus applicable margin		5.62	%		—		6.47	%		—
Swingline/Base Rate - payable to lenders at ABR plus applicable margin		7.75	%		—		8.50	%		—
Amortizing Notes (1)					19,278					31,360
Notes payable and other					15,103					17,129
Total debt					2,249,253					2,569,744
Less: debt issuance costs, net					58,493					62,200
Total debt, net of debt issuance costs					2,190,760					2,507,544
Less: current portion of long-term debt					41,445					52,340
Total long-term debt, net of current portion				$	2,149,315				$	2,455,204

(1)

See Note 7 for discussion of Amortizing Notes.

We are required to disclose the fair value of financial instruments for which it is practicable to estimate the fair value, even though these instruments are not recognized at fair value in the consolidated balance sheets. The following table presents the carrying value and estimated fair values of the Company’s debt obligations as of June 30, 2026 (in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of June 30, 2026		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan	$	2,214,872	$	—	$	2,214,872	$	—
Amortizing Notes		19,278		—		19,302		—
Total debt instruments	$	2,234,150	$	—	$	2,234,174	$	—

The following discussion summarizes the debt agreements and related modification for the six months ended June 30, 2026 and the year ended December 31, 2025.

First Lien Credit Agreement

On March 5, 2019, the Company entered into a First Lien Credit Agreement (the “First Lien”), with Morgan Stanley Senior Funding, Inc., as the Administrative Agent and the Collateral Agent.

On December 11, 2024, we amended the First Lien to refinance the outstanding principal by establishing a Tranche B-5 Term Loan (“Tranche B-5”) in an aggregate principal amount of $2,553.2 million at a rate equal to Secured Overnight Financing Rate (“SOFR”) plus 2.50% or Alternate Base Rate (“ABR”) plus 1.50% with a maturity date of February 21, 2031. Principal payments were due on the last business day of each quarter, which commenced in the first fiscal quarter of 2025 and equated to 0.25% of the principal at issuance, with a balloon payment due February 21, 2031.

On May 28, 2026, we used a portion of the net proceeds received from the Community Living divestiture to repay $300.0 million of the borrowing under Tranche B-5 and amended the First Lien to establish a new Tranche B-6 Term Loan (“Tranche B-6”) in an aggregate principal amount of $2,214.9 million. The proceeds from Tranche B-6 borrowings were used to refinance the equivalent amount of the remaining Tranche B-5, after the aforementioned debt paydown, at a rate equal to SOFR plus 2.00% or ABR plus 1.00% with a maturity date of February 21, 2031. The transaction was accounted for as a debt modification. Principal payments are due on the last business day of each quarter, which will commence in the third fiscal quarter of 2026 and equate to 0.25% of the principal at issuance, with a balloon payment due February 21, 2031.

Revolving Credit Facility

The First Lien also extends credit in the form of a Revolving Credit Facility with a borrowing capacity of $475.0 million (the “Revolver”), of which up to $50.0 million is available as swingline loans and up to $82.5 million is available as letters of credit (the “LC Sublimit”). The Revolver will mature on June 30, 2028. In connection with the First Lien debt modification on May 28, 2026, borrowings of the Revolver bear interest at a rate equal to SOFR (with a floor of 0.00%) plus 2.00% for the Revolving Credit Loans or ABR (with a floor of 0.00%) plus 1.00% for the Swingline Loans. Prior to the debt modification, borrowings bore interest at a rate equal to SOFR (with a floor of 0.00%) plus 2.75% for the Revolving Credit Loans and ABR (with a floor of 0.00%) plus 1.75% for the Swingline Loans. As of June 30, 2026 and December 31, 2025, the Company had $475.0 million of borrowing capacity available under the Revolver as there were no borrowings under the Revolver or letters of credit outstanding.

The Company’s First Lien also provides for an additional $65.0 million of letter of credit commitments (the “LC Facility”), which are not subject to the LC Sublimit and do not reduce the Revolver borrowing capacity. As of June 30, 2026, there were $63.9 million of letters of credit outstanding under the LC Facility, resulting in an available borrowing capacity of $1.1 million. As of December 31, 2025, there were $62.8 million of letters of credit outstanding under the LC Facility, resulting in an available borrowing capacity of $2.2 million.

Derivative Financial Instruments

To manage fluctuations in cash flows resulting from changes in the variable interest rates, the Company entered into receive-variable, pay-fixed interest rate swap agreements. The following table summarizes our interest rate swaps designated as cash flow hedges (in millions):


	Notional Amount as of
Financial Institution	June 30, 2026		December 31, 2025		Effective Dates	Fixed Rates
Credit Agricole Corporate and Investment Bank	$	500	$	500	1-year period ending September 30, 2026		3.72500	%
Mizuho Capital Markets		500		500	1-year period ending September 30, 2026		3.61121	%
Credit Agricole Corporate and Investment Bank		250		250	3-year period ending September 30, 2028		3.33150	%
Morgan Stanley		250		250	3-year period ending September 30, 2028		3.17700	%
Existing contracts	$	1,500	$	1,500

Mizuho Capital Markets	$	500	$	500	2-year period ending September 30, 2028		3.20220	%
Forward starting contracts (1)	$	500	$	500

(1)

During the fourth fiscal quarter of 2025, we entered into a forward starting interest rate swap agreement, with a $500 million notional amount, to hedge the cash flow risk of variability in interest payment on our variable rate borrowings. The effective date of the forward starting interest rate swap agreement is September 30, 2026. As of June 30, 2026, this contract meets the criteria of a cash flow hedge.

The net fair value of the cash flow hedges as of June 30, 2026 and December 31, 2025 was a $14.3 million asset and a $0.4 million liability, respectively, and is reflected in prepaid expenses and other current assets, other assets, accrued expenses and long-term liabilities, as applicable, in the unaudited condensed consolidated balance sheets. Refer to Note 9 for details. The fair values of our interest rate swaps are based upon Level 2 inputs, which include valuation models. The key inputs for the valuation models are quoted market prices, interest rates, forward yield curves, and credit risk adjustments that are necessary to reflect the probability of default by the counterparty or us.

Amounts reported in accumulated other comprehensive income (“AOCI”) related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. Net interest received, including payments made or received under the cash flow hedges, was $0.4 million and $1.0 million for the three and six months ended June 30, 2026, respectively, as compared to $4.4 million and $8.8 million for the three and six months ended June 30, 2025, respectively. The Company expects approximately $6.5 million of pre-tax gains to be reclassified out of AOCI into earnings within the next twelve months.

The debt modification did not impact the effectiveness of the cash flow hedge arrangements outstanding as of June 30, 2026.

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2026	Jul. 28, 2026
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001865782
Document Fiscal Period Focus	Q2
Document Period End Date	Jun. 30, 2026
Document Fiscal Year Focus	2026
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-41938
Entity Registrant Name	BrightSpring Health Services, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2956404
Entity Address, Address Line One	805 N. Whittington Parkway
Entity Address, City or Town	Louisville
Entity Address, State or Province	KY
Entity Address, Postal Zip Code	40222
City Area Code	502
Local Phone Number	394-2100
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding (in shares)		197,864,241
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	BTSG
Security Exchange Name	NASDAQ
6.75% Tangible Equity Unit [Member]
Document Information [Line Items]
Title of 12(b) Security	6.75% Tangible Equity Units
Trading Symbol	BTSGU
Security Exchange Name	NASDAQ

Debt and Derivatives - Summary of Carrying Value and Estimated Fair Values of Debt Obligations (Details) $ in Millions	Jun. 30, 2026 USD ($)
Debt Instrument [Line Items]
Total debt instruments, fair value	$ 2,234,150
Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments, fair value	2,234,174
First Lien Term Loan
Debt Instrument [Line Items]
Total debt instruments, fair value	2,214,872
First Lien Term Loan \| Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments, fair value	2,214,872
Amortizing Notes
Debt Instrument [Line Items]
Total debt instruments, fair value	19,278
Amortizing Notes \| Significant Other Observable Inputs (Level 2)
Debt Instrument [Line Items]
Total debt instruments, fair value	$ 19,302

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

Detail of Certain Balance Sheet Accounts

6 Months Ended

Jun. 30, 2026

Disclosure Text Block Supplement [Abstract]

Detail of Certain Balance Sheet Accounts

9. Detail of Certain Balance Sheet Accounts

Prepaid expenses and other current assets consist of the following (in thousands):


	June 30, 2026		December 31, 2025
Non-trade receivables	$	61,709	$	38,196
Income tax receivable		49,050		864
Rebate receivable		45,393		32,407
Inventory returns receivable		11,594		11,019
Dues and subscriptions		11,573		7,588
Prepaid insurance		5,440		13,255
Other prepaid expenses and current assets		20,404		15,263
Total prepaid expenses and other current assets	$	205,163	$	118,592

Other assets consist of the following (in thousands):


	June 30, 2026		December 31, 2025
Insurance recoveries	$	40,760	$	7,251
Interest rate swaps		14,167		1,181
Other investments		7,544		7,481
Cloud computing		6,863		6,017
Deposits		5,816		5,722
Deferred compensation		5,022		4,702
Notes receivable		1,940		4,012
Other assets		3,122		3,346
Total other assets	$	85,234	$	39,712

Accrued expenses consist of the following (in thousands):


	June 30, 2026		December 31, 2025
Wages and payroll taxes	$	153,232	$	131,162
Compensated absences		35,152		31,543
Health insurance reserves		28,011		15,389
Workers compensation insurance reserves		19,992		24,897
Legal settlements and professional fees		18,569		10,525
Checks in excess of cash balance		17,731		34,824
General and professional liability insurance reserves		16,376		7,696
Deferred revenue		13,083		9,039
Property insurance reserves		8,085		11,170
Automobile insurance reserves		6,529		5,585
Taxes other than income taxes		4,243		3,506
Other		50,698		47,688
Total accrued expenses	$	371,701	$	333,024

Long-term liabilities consist of the following (in thousands):


	June 30, 2026		December 31, 2025
General and professional liability insurance reserves	$	37,219	$	25,032
Workers compensation insurance reserves		24,591		25,369
Automobile insurance reserves		7,795		9,849
Deferred compensation		5,022		4,702
Other		1,985		1,613
Total long-term liabilities	$	76,612	$	66,565

Debt and Derivatives - Schedule of Interest Rate Swap with Notional Value (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Existing contracts
Derivative [Line Items]
Derivative, Notional Amount	$ 1,500	$ 1,500
Existing contracts \| Credit Agricole Corporate and Investment Bank
Derivative [Line Items]
Derivative, Notional Amount	$ 500	500
Derivative, description of terms	1-year period ending September 30, 2026
Fixed rate	3.725%
Existing contracts \| Mizuho Capital Markets
Derivative [Line Items]
Derivative, Notional Amount	$ 500	500
Derivative, description of terms	1-year period ending September 30, 2026
Fixed rate	3.61121%
Existing contracts \| Credit Agricole Corporate and Investment Bank
Derivative [Line Items]
Derivative, Notional Amount	$ 250	250
Derivative, description of terms	3-year period ending September 30, 2028
Fixed rate	3.3315%
Existing contracts \| Morgan Stanley
Derivative [Line Items]
Derivative, Notional Amount	$ 250	250
Derivative, description of terms	3-year period ending September 30, 2028
Fixed rate	3.177%
Forward starting contracts
Derivative [Line Items]
Derivative, Notional Amount	$ 500	500
Forward starting contracts \| Mizuho Capital Markets
Derivative [Line Items]
Derivative, Notional Amount	$ 500	$ 500
Derivative, description of terms	2-year period ending September 30, 2028
Fixed rate	3.2022%

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2026

Discontinued Operations and Disposal Groups [Abstract]

Summary of the Reconciles the Gross Proceeds With the Gain on Sale, Net of Tax for the Sale, the Financial Results, Aggregate Carrying Amounts of Assets and Liabilities Held for Sale and Significant Non-cash Items and Purchases of Property and Equipment

The following table reconciles the gross proceeds with the gain on sale, net of tax for the sale of the Community Living business:


	For the Six Months Ended
	June 30,
	2026
Gross proceeds	$	835,000
Less: certain post-closing adjustments		12,617
Less: direct costs to sell		13,854
Less: carrying amount of Community Living business		706,661
Gain on sale of discontinued operations	$	101,868
Less: current and deferred tax impact		72,218
Net gain on sale of discontinued operations	$	29,650

The following table presents the financial results of the Community Living business (in thousands):


	For the Three Months Ended					For the Six Months Ended
	June 30,					June 30,
	2026			2025		2026		2025
Services revenue	$	—		$	307,683	$	306,646	$	606,789
Cost of services		—			211,614		206,585		415,797
Gross profit		—			96,069		100,061		190,992
Selling, general, and administrative expenses		7,703			63,739		45,669		124,483
Operating (loss) income of discontinued operations		(7,703	)		32,330		54,392		66,509
Interest expense, net		—			7,590		6,677		15,497
(Loss) gain on sale of discontinued operations		(1,544	)		—		101,868		—
(Loss) income of discontinued operations before incomes taxes		(9,247	)		24,740		149,583		51,012
Income tax (benefit) expense of discontinued operations		(6,852	)		5,739		77,651		12,217
(Loss) income from discontinued operations, net of income taxes	$	(2,395	)	$	19,001	$	71,932	$	38,795

The following table presents the aggregate carrying amounts of assets and liabilities held for sale for the Community Living business as of December 31, 2025 in the unaudited condensed consolidated balance sheet (in thousands):


Assets
Current assets:
Cash and cash equivalents	$	107
Accounts receivable, net of allowance for credit losses		136,875
Inventories		3,294
Prepaid expenses and other current assets		2,717
Total current assets held for sale		142,993
Property and equipment, net of accumulated depreciation of $104,314		83,465
Goodwill		307,640
Intangible assets, net of accumulated amortization		216,192
Operating lease right-of-use assets, net		129,005
Other assets		2,894
Total assets held for sale	$	882,189
Liabilities
Current liabilities:
Trade accounts payable	$	25,081
Accrued expenses		59,038
Current portion of obligations under operating leases		32,749
Current portion of obligations under financing leases		7,691
Total current liabilities held for sale		124,559
Obligations under operating leases, net of current portion		57,771
Obligations under financing leases, net of current portion		12,766
Deferred income taxes, net		390
Long-term liabilities		508
Total liabilities held for sale	$	195,994

The following table presents the significant non-cash items and purchases of property and equipment for the discontinued operations that are included in the accompanying unaudited condensed consolidated statements of cash flows (in thousands):


	For the Six Months Ended
	June 30,
	2026			2025
Cash flows from operating activities of discontinued operations:
Depreciation and amortization	$	—		$	1,329
Share-based compensation		(9,296	)		6,501
Gain on sale of discontinued operations		(101,868	)		—

Cash flows used in investing activities of discontinued operations:
Purchases of property and equipment		3,085			5,868

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 102
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483474/205-20-55-102

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 103
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483474/205-20-55-103

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

+ Details

Acquisitions - Schedule of Consideration Paid for Acquisitions and Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2025	Mar. 31, 2026	Dec. 31, 2025	Jun. 30, 2026
Business Combination [Line Items]
Goodwill	$ 2,545,673		$ 2,545,673	$ 2,535,244
Amedisys and LHC Branches Acquisition
Business Combination [Line Items]
Accounts receivable	35,456		35,456
Prepaid expenses and other current assets	32		32
Property and equipment	5,633		5,633
Goodwill	164,753		164,753
Intangible assets	62,897		62,897
Operating lease right-of-use assets	12,604		12,604
Other assets	88		88
Trade accounts payable	1,881		1,881
Accrued expenses	12,313		12,313
Current portion of obligations under operating leases	4,177		4,177
Current portion of obligations under financing leases	1,797		1,797
Obligations under operating leases, net of current portion	8,427		8,427
Obligations under financing leases, net of current portion	3,587		3,587
Long-term liabilities	2,773		2,773
Redeemable noncontrolling interests	8,084		8,084
Noncontrolling interest	(35)		(35)
Aggregate purchase price, net of cash acquired	$ 238,459	$ 42,200	$ 246,400

Goodwill and Intangible Assets - Summary of Changes to Goodwill (Parenthetical) (Details) $ in Millions	Jun. 30, 2026 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Net of accumulated impairment losses	$ 40.9

Earnings Per Share ("EPS")

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

Earnings Per Share ("EPS")

10. Earnings Per Share (“EPS”)

Basic net income (loss) per share of common stock excludes dilution and is reported separately for continuing operations and discontinued operations. Basic net income (loss) per share of common stock for continuing operations and discontinued operations is calculated by dividing net income (loss) from continuing operations and discontinued operations attributable to common shareholders by the weighted average number of shares outstanding for the reporting period. Diluted net income per share of common stock is computed by giving effect to the weighted average of all potentially dilutive common stock. In periods of net loss, no potentially dilutive common shares are included in the diluted shares outstanding as the effect is anti-dilutive.

The number of additional shares of common stock related to restricted stock units (“RSUs”) and stock option awards is calculated using the treasury stock method, if dilutive.

For the three and six months ended June 30, 2026 and 2025, the TEUs were assumed to be outstanding at the minimum settlement amount for weighted-average shares for basic EPS. For the three and six months ended June 30, 2026 and 2025, the Company’s average applicable market value was greater than $15.28, resulting in no dilutive impact to EPS for TEUs. See Note 7 for further discussion of TEUs.

The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common shareholders (in thousands, except per share amounts):


	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2026			2025			2026			2025
Numerator:
Net income from continuing operations	$	86,604		$	8,541		$	160,887		$	17,757
Less: Net loss attributable to noncontrolling interests		(81	)		(666	)		(238	)		(1,198	)
Net income from continuing operations attributable to common shareholders		86,685			9,207			161,125			18,955
Net (loss) income from discontinued operations		(2,395	)		19,001			71,932			38,795
Net income attributable to common shareholders	$	84,290		$	28,208		$	233,057		$	57,750

Denominator:
Weighted-average shares outstanding - basic		206,042			201,807			205,381			200,516

Effect of dilutive securities:
Stock options		8,947			8,098			9,468			8,167
RSUs		5,287			6,431			6,342			6,280
TEUs		—			—			—			—
Weighted-average shares outstanding - diluted		220,276			216,336			221,191			214,963

Basic income (loss) per share attributable to common shareholders:
Continuing operations	$	0.42		$	0.05		$	0.78		$	0.09
Discontinued operations	$	(0.01	)	$	0.09		$	0.35		$	0.20
Net income per share	$	0.41		$	0.14		$	1.13		$	0.29

Diluted income (loss) per share attributable to common shareholders:
Continuing operations	$	0.39		$	0.04		$	0.73		$	0.09
Discontinued operations	$	(0.01	)	$	0.09		$	0.32		$	0.18
Net income per share	$	0.38		$	0.13		$	1.05		$	0.27

There were no potentially dilutive common share equivalents excluded from the computation of diluted net income (loss) per share for the three and six months ended June 30, 2026. For the three and six months ended June 30, 2025, there were an immaterial number of potentially dilutive common share equivalents excluded from the computation of diluted net income (loss) per share because their effect would have been anti-dilutive.

Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following tables set forth information about the Company’s reportable segments, along with the items necessary to reconcile the segment information to the totals reported in the Company’s unaudited condensed consolidated statements of operations as follows (in thousands):


	For the Three Months Ended June 30, 2026
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	3,407,173	$	—	$	3,407,173
Services revenue		—		465,967		465,967
Cost of drugs		2,916,899		—		2,916,899
Cost of services		—		271,402		271,402
Other direct costs (1)		192,093		—		192,093
Segment selling, general, and administrative expenses (2)		143,612		128,515		272,127
Segment depreciation and amortization expense (3)		25,480		8,811		34,291
Segment EBITDA	$	180,049	$	74,861	$	254,910


	For the Three Months Ended June 30, 2025
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	2,790,101	$	—	$	2,790,101
Services revenue		—		357,597		357,597
Cost of drugs		2,377,477		—		2,377,477
Cost of services		—		216,444		216,444
Other direct costs (1)		178,925		—		178,925
Segment selling, general, and administrative expenses (2)		136,040		91,871		227,911
Segment depreciation and amortization expense (3)		27,033		7,174		34,207
Segment EBITDA	$	124,692	$	56,456	$	181,148


	For the Six Months Ended June 30, 2026
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	6,578,522	$	—	$	6,578,522
Services revenue		—		908,339		908,339
Cost of drugs		5,589,692		—		5,589,692
Cost of services		—		532,326		532,326
Other direct costs (1)		389,875		—		389,875
Segment selling, general, and administrative expenses (2)		300,646		250,937		551,583
Segment depreciation and amortization expense (3)		50,808		15,765		66,573
Segment EBITDA	$	349,117	$	140,841	$	489,958


	For the Six Months Ended June 30, 2025
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	5,322,272	$	—	$	5,322,272
Services revenue		—		703,555		703,555
Cost of drugs		4,525,053		—		4,525,053
Cost of services		—		427,989		427,989
Other direct costs (1)		359,564		—		359,564
Segment selling, general, and administrative expenses (2)		251,778		181,973		433,751
Segment depreciation and amortization expense (3)		54,541		13,943		68,484
Segment EBITDA	$	240,418	$	107,536	$	347,954

(1)

Other direct costs primarily includes direct labor costs, delivery costs, insurance, and depreciation and amortization expense that relates to revenue-generating assets.

(2)

Segment selling, general, and administrative expense includes indirect labor costs, depreciation and amortization, insurance, rent, lease, supplies, professional services, maintenance, repairs, utilities, and communications expense.

(3)

Total segment depreciation and amortization expense is presented in other direct costs, costs of services, and segment general and administrative expenses, based on the associated asset.


	For the Three Months Ended				For the Six Months Ended
	June 30,				June 30,
	2026		2025		2026		2025
Reconciliation of income:
Total Segment EBITDA	$	254,910	$	181,148	$	489,958	$	347,954
Segment depreciation and amortization		34,291		34,207		66,573		68,484
Expenses not allocated at segment level:
Selling, general, and administrative expenses		83,096		90,752		157,601		165,987
Depreciation and amortization		7,132		7,632		13,944		14,187
Interest expense, net		36,879		38,778		75,494		80,541
Income tax expense		6,908		1,238		15,459		998
Net income from continuing operations	$	86,604	$	8,541	$	160,887	$	17,757

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

Discontinued Operations

6 Months Ended

Jun. 30, 2026

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

2. Discontinued Operations

On January 17, 2025, BrightSpring entered into a definitive agreement to sell its Community Living business to National Mentor Holdings, Inc. (the “Purchaser”) for $835.0 million in cash upon closing, subject to certain post-closing adjustments. We entered into the transaction in order to streamline our service offerings and further focus on the senior and specialty populations. On March 30,

2026, the Company completed the transaction pursuant to the terms of the definitive agreement for cash proceeds of $810.9 million, resulting in a pre-tax gain on sale of $101.9 million.

The following table reconciles the gross proceeds with the gain on sale, net of tax for the sale of the Community Living business:


	For the Six Months Ended
	June 30,
	2026
Gross proceeds	$	835,000
Less: certain post-closing adjustments		12,617
Less: direct costs to sell		13,854
Less: carrying amount of Community Living business		706,661
Gain on sale of discontinued operations	$	101,868
Less: current and deferred tax impact		72,218
Net gain on sale of discontinued operations	$	29,650

The Company determined the divestiture of the Community Living business represents a strategic shift that will have a major effect on its business and concluded the criteria for classification as discontinued operations were met during the first fiscal quarter of 2025. Accordingly, the Community Living business is reported as discontinued operations in accordance with ASC 205-20, Discontinued Operations. The Community Living business was historically presented as a part of the Provider Services reportable segment.

In accordance with ASC 205-20, Allocation of Interest to Discontinued Operations, the Company elected to allocate interest expense to discontinued operations for the Company’s debt that is not directly attributed to the Community Living business. Interest expense was allocated based on a ratio of net assets held for sale to the sum of consolidated net assets and consolidated debt. In addition, upon closing of the divestiture, we entered into a transition services agreement (“TSA”) with the Purchaser to support the Purchaser's post-closing operations of the Community Living business by providing the Purchaser with certain transition services in exchange for service fees in the form of both fixed-price and pass through costs over the 18 months following the close of the transaction. Transition services primarily include finance and accounting, human resources, IT, facilities management, and compliance services. The fees associated with the services rendered under the TSA are presented in selling, general, and administrative expenses in the unaudited condensed consolidated statement of operations and are not material to our results of operations.

The financial results of the Community Living business are presented as (loss) income from discontinued operations on our unaudited condensed consolidated statements of operations. The following table presents the financial results of the Community Living business (in thousands):


	For the Three Months Ended					For the Six Months Ended
	June 30,					June 30,
	2026			2025		2026		2025
Services revenue	$	—		$	307,683	$	306,646	$	606,789
Cost of services		—			211,614		206,585		415,797
Gross profit		—			96,069		100,061		190,992
Selling, general, and administrative expenses		7,703			63,739		45,669		124,483
Operating (loss) income of discontinued operations		(7,703	)		32,330		54,392		66,509
Interest expense, net		—			7,590		6,677		15,497
(Loss) gain on sale of discontinued operations		(1,544	)		—		101,868		—
(Loss) income of discontinued operations before incomes taxes		(9,247	)		24,740		149,583		51,012
Income tax (benefit) expense of discontinued operations		(6,852	)		5,739		77,651		12,217
(Loss) income from discontinued operations, net of income taxes	$	(2,395	)	$	19,001	$	71,932	$	38,795


Assets
Current assets:
Cash and cash equivalents	$	107
Accounts receivable, net of allowance for credit losses		136,875
Inventories		3,294
Prepaid expenses and other current assets		2,717
Total current assets held for sale		142,993
Property and equipment, net of accumulated depreciation of $104,314		83,465
Goodwill		307,640
Intangible assets, net of accumulated amortization		216,192
Operating lease right-of-use assets, net		129,005
Other assets		2,894
Total assets held for sale	$	882,189
Liabilities
Current liabilities:
Trade accounts payable	$	25,081
Accrued expenses		59,038
Current portion of obligations under operating leases		32,749
Current portion of obligations under financing leases		7,691
Total current liabilities held for sale		124,559
Obligations under operating leases, net of current portion		57,771
Obligations under financing leases, net of current portion		12,766
Deferred income taxes, net		390
Long-term liabilities		508
Total liabilities held for sale	$	195,994


	For the Six Months Ended
	June 30,
	2026			2025
Cash flows from operating activities of discontinued operations:
Depreciation and amortization	$	—		$	1,329
Share-based compensation		(9,296	)		6,501
Gain on sale of discontinued operations		(101,868	)		—

Cash flows used in investing activities of discontinued operations:
Purchases of property and equipment		3,085			5,868

Tangible Equity Units ("TEUs") - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2024	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025	May 01, 2024
Minimum
Class of Stock [Line Items]
Mandatory conversion to common stock				26,200,000
Average applicable market value		$ 13		$ 13
Maximum
Class of Stock [Line Items]
Mandatory conversion to common stock				30,800,000
Average applicable market value		$ 15.28		$ 15.28
Senior Amortizing Note
Class of Stock [Line Items]
Maturity date	Feb. 01, 2027
Amortizing Notes
Class of Stock [Line Items]
Maturity date	Feb. 01, 2027
Long-term portion of the amortizing notes						$ 6.6
Short-term portion of the amortizing notes		$ 19.3		$ 19.3		$ 24.8
Cash installment per unit	$ 0.8438						$ 0.8531
Percentage of aggregate annual quarterly cash installments equivalent per year	6.75%
TEU installment payments		$ 6.7	$ 6.7	$ 13.5	$ 13.5
Purchase Contracts
Class of Stock [Line Items]
Units converted at holder's option		2,526,146	0	2,526,146	0
TEUs
Class of Stock [Line Items]
Tangible equity unit	8,000,000
TEU price per share	$ 50
TEUs \| Minimum
Class of Stock [Line Items]
Average applicable market value		$ 15.28	$ 15.28	$ 15.28	$ 15.28

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Tax Disclosure [Abstract]
Income tax rate	$ 16.9	$ 1.4	$ 29.3	$ 3.7

Detail of Certain Balance Sheet Accounts - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Disclosure Text Block Supplement [Abstract]
Non-trade receivables	$ 61,709	$ 38,196
Income tax receivable	49,050	864
Rebate receivable	45,393	32,407
Inventory returns receivable	11,594	11,019
Dues and subscriptions	11,573	7,588
Prepaid insurance	5,440	13,255
Other prepaid expenses and current assets	20,404	15,263
Total prepaid expenses and other current assets	$ 205,163	$ 118,592

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 550,381	$ 88,370
Accounts receivable, net of allowance for credit losses	1,139,420	989,719
Inventories	575,009	815,180
Prepaid expenses and other current assets	205,163	118,592
Total current assets	2,469,973	2,894,050
Property and equipment, net of accumulated depreciation of $438,963 and $404,878 at June 30, 2026 and December 31, 2025, respectively	213,866	204,689
Goodwill	2,535,244	2,545,673
Intangible assets, net of accumulated amortization	514,424	557,555
Operating lease right-of-use assets, net	166,976	171,632
Other assets	85,234	39,712
Total assets	5,985,717	6,413,311
Current liabilities:
Trade accounts payable	1,090,915	1,217,946
Accrued expenses	371,701	333,024
Current portion of obligations under operating leases	44,663	42,936
Current portion of obligations under financing leases	6,909	6,794
Current portion of long-term debt	41,445	52,340
Total current liabilities	1,555,633	1,849,034
Obligations under operating leases, net of current portion	132,046	135,420
Obligations under financing leases, net of current portion	13,273	14,544
Long-term debt, net of current portion	2,149,315	2,455,204
Deferred income taxes, net	636	6,178
Long-term liabilities	76,612	66,565
Total liabilities	3,927,515	4,526,945
Redeemable noncontrolling interests	9,417	11,227
Shareholders' equity
Common stock, $0.01 par value, 1,500,000,000 shares authorized, 197,509,491 and 192,124,125 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1,975	1,921
Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and outstanding at June 30, 2026 and December 31, 2025
Additional paid-in capital	2,004,123	1,954,482
Retained earnings (accumulated deficit)	38,434	(74,647)
Accumulated other comprehensive income (loss)	4,185	(6,691)
Total shareholders'' equity	2,048,717	1,875,065
Noncontrolling interest	68	74
Total equity	2,048,785	1,875,139
Total liabilities, redeemable noncontrolling interests, and equity	5,985,717	6,413,311
Discontinued operation held for sale
Current assets:
Current assets held for sale	0	882,189
Current liabilities:
Current liabilities held for sale	$ 0	$ 195,994

Detail of Certain Balance Sheet Accounts - Schedule of Long-Term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Disclosure Text Block Supplement [Abstract]
General and professional liability insurance reserves	$ 37,219	$ 25,032
Workers compensation insurance reserves	24,591	25,369
Automobile insurance reserves	7,795	9,849
Deferred compensation	5,022	4,702
Other	1,985	1,613
Total long-term liabilities	$ 76,612	$ 66,565

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Total revenues	$ 3,873,140	$ 3,147,698	$ 7,486,861	$ 6,025,827
Cost of goods	3,108,992	2,556,402	5,979,567	4,884,617
Cost of services	271,402	216,444	532,326	427,989
Gross profit	492,746	374,852	974,968	713,221
Selling, general, and administrative expenses	362,355	326,295	723,128	613,925
Operating income	130,391	48,557	251,840	99,296
Interest expense, net	36,879	38,778	75,494	80,541
Income from continuing operations before income taxes	93,512	9,779	176,346	18,755
Income tax expense	6,908	1,238	15,459	998
Income from continuing operations, net of income taxes	86,604	8,541	160,887	17,757
(Loss) income from discontinued operations, net of income taxes	(2,395)	19,001	71,932	38,795
Net income	84,209	27,542	232,819	56,552
Net loss attributable to noncontrolling interests included in continuing operations	(81)	(666)	(238)	(1,198)
Net income attributable to BrightSpring Health Services, Inc. and subsidiaries	$ 84,290	$ 28,208	$ 233,057	$ 57,750
Basic income (loss) per share attributable to common shareholders:
Continuing operations	$ 0.42	$ 0.05	$ 0.78	$ 0.09
Discontinued operations	(0.01)	0.09	0.35	0.2
Net income per share	0.41	0.14	1.13	0.29
Diluted income (loss) per share attributable to common shareholders:
Continuing operations	0.39	0.04	0.73	0.09
Discontinued operations	(0.01)	0.09	0.32	0.18
Net income per share	$ 0.38	$ 0.13	$ 1.05	$ 0.27
Weighted average shares outstanding:
Basic	206,042	201,807	205,381	200,516
Diluted	220,276	216,336	221,191	214,963
Products
Total revenues	$ 3,407,173	$ 2,790,101	$ 6,578,522	$ 5,322,272
Services
Total revenues	$ 465,967	$ 357,597	$ 908,339	$ 703,555

Goodwill and Intangible Assets

6 Months Ended

Jun. 30, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

5. Goodwill and Intangible Assets

A summary of changes to goodwill, by reportable segment, is as follows (in thousands):


	Goodwill
	Pharmacy Solutions		Provider Services			Total
Goodwill at January 1, 2026*	$	841,052	$	1,704,621		$	2,545,673
Measurement period adjustments		—		(10,289	)		(10,289	)
Foreign currency adjustments		—		(140	)		(140	)
Goodwill at June 30, 2026*	$	841,052	$	1,694,192		$	2,535,244

* For the periods presented, the carrying amount of goodwill is presented net of accumulated impairment losses of $40.9 million, which were incurred in fiscal year 2022.

Intangible assets are as follows (in thousands):


	June 30, 2026						December 31, 2025
	Gross		Accumulated Amortization		Net Carrying Value		Gross		Accumulated Amortization		Net Carrying Value		Life (Years)
Customer relationships	$	501,510	$	381,851	$	119,659	$	502,160	$	356,146	$	146,014	5-20
Trade names		318,768		165,644		153,124		318,768		154,601		164,167	2-20
Licenses		67,120		21,011		46,109		67,395		18,886		48,509	10-20
Doctor/payor network		3,300		2,922		378		5,650		4,987		663	5-8
Covenants not to compete		3,834		2,438		1,396		6,654		4,717		1,937	2-7
Other intangible assets		10,940		8,707		2,233		10,940		7,925		3,015	5-7
Total definite-lived assets	$	905,472	$	582,573	$	322,899	$	911,567	$	547,262	$	364,305
Licenses		191,525		—		191,525		193,250		—		193,250	Indefinite
Total intangible assets	$	1,096,997	$	582,573	$	514,424	$	1,104,817	$	547,262	$	557,555

Amortization expense for the three and six months ended June 30, 2026 was $22.4 million and $43.1 million, respectively, as compared to $23.6 million and $47.0 million for the three and six months ended June 30, 2025, respectively.

Revenue

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

Revenue

3. Revenue

The Company is substantially dependent on revenues received under contracts with federal, state, and local government agencies. Operating funding sources are generally earned from Medicaid, Medicare, commercial insurance reimbursement, and from private and other payors. There is no single customer whose revenue was 10% or more of our consolidated revenue during the periods presented. The following tables set forth revenue by payor type (in millions):


	Pharmacy Solutions
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
	2026					2025					2026					2025
	Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue
Commercial insurance	$	1,053.5		27.2	%	$	742.0		23.6	%	$	2,012.9		26.9	%	$	1,416.5		23.5	%
Medicaid		339.3		8.8	%		266.2		8.5	%		647.9		8.7	%		504.4		8.4	%
Medicare Part A		136.3		3.5	%		138.9		4.4	%		274.0		3.7	%		279.3		4.6	%
Medicare Part B		18.3		0.5	%		18.7		0.6	%		38.6		0.5	%		38.2		0.6	%
Medicare Part C		653.7		16.9	%		555.6		17.7	%		1,256.1		16.8	%		1,043.3		17.3	%
Medicare Part D		1,149.9		29.7	%		1,008.4		32.0	%		2,224.0		29.7	%		1,919.3		31.9	%
Private & other		56.1		1.4	%		60.3		1.8	%		125.0		1.6	%		121.3		2.0	%
	$	3,407.1		88.0	%	$	2,790.1		88.6	%	$	6,578.5		87.9	%	$	5,322.3		88.3	%


	Provider Services
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
	2026					2025					2026					2025
	Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue
Commercial insurance	$	59.0		1.5	%	$	44.1		1.4	%	$	113.9		1.5	%	$	85.5		1.4	%
Medicaid		97.3		2.5	%		88.5		2.8	%		194.4		2.6	%		173.6		2.9	%
Medicare Part A		173.5		4.5	%		125.8		4.0	%		344.7		4.6	%		248.2		4.1	%
Medicare Part B		12.3		0.3	%		1.4		0.0	%		13.8		0.2	%		2.9		0.0	%
Medicare Part C		66.8		1.7	%		34.6		1.1	%		131.4		1.8	%		67.2		1.1	%
Private & other		57.1		1.5	%		63.2		2.1	%		110.2		1.4	%		126.1		2.2	%
	$	466.0		12.0	%	$	357.6		11.4	%	$	908.4		12.1	%	$	703.5		11.7	%


	Consolidated
	For the Three Months Ended June 30,										For the Six Months Ended June 30,
	2026					2025					2026					2025
	Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue			Revenue		% of Revenue
Commercial insurance	$	1,112.5		28.7	%	$	786.1		25.0	%	$	2,126.8		28.4	%	$	1,502.0		24.9	%
Medicaid		436.6		11.3	%		354.7		11.3	%		842.3		11.3	%		678.0		11.3	%
Medicare Part A		309.8		8.0	%		264.7		8.4	%		618.7		8.3	%		527.5		8.7	%
Medicare Part B		30.6		0.8	%		20.1		0.6	%		52.4		0.7	%		41.1		0.6	%
Medicare Part C		720.5		18.6	%		590.2		18.8	%		1,387.5		18.6	%		1,110.5		18.4	%
Medicare Part D		1,149.9		29.7	%		1,008.4		32.0	%		2,224.0		29.7	%		1,919.3		31.9	%
Private & other		113.2		2.9	%		123.5		3.9	%		235.2		3.0	%		247.4		4.2	%
	$	3,873.1		100.0	%	$	3,147.7		100.0	%	$	7,486.9		100.0	%	$	6,025.8		100.0	%

Refer to Note 11 for the disaggregation of revenue by reportable segment.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2026
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of BrightSpring Health Services, Inc. and its subsidiaries. The Company consolidates its majority-owned and controlled entities, including variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. We record a noncontrolling interest for the allocable portion of income or loss and comprehensive income or loss to which the noncontrolling interest holders are entitled based upon their ownership share of the affiliate. The Company determined noncontrolling interests for certain of these VIEs to be redeemable noncontrolling interests, which are presented in the unaudited condensed consolidated balance sheets as redeemable noncontrolling interests.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year. As discussed in Note 2, the Community Living business met the criteria to be reported as discontinued operations and held for sale during the first fiscal quarter of 2025. Therefore, the Company has reported the historical results of the Community Living business, including the results of operations and cash flows as discontinued operations for all periods presented herein, and related assets and liabilities, as held for sale as of December 31, 2025. Unless otherwise noted, all activities and amounts reported in the accompanying notes to the unaudited condensed consolidated financial statements relate to the continuing operations of the Company and exclude activities and amounts related to the Community Living business. This report should be read in conjunction with our consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by the rules and regulations of the Securities and Exchange Commission.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts and related disclosures. We rely on historical experience and on various other assumptions that we believe to be reasonable under the circumstances to make judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates are involved in the valuation of accounts receivable, inventory, intangible assets, derivatives, contingent consideration, taxes, insurance reserves, share-based compensation, and goodwill. Actual amounts may differ from these estimates.
Commitments and Contingencies	Commitments and Contingencies The Company is party to various legal and/or administrative proceedings arising out of the operation of our programs and arising in the ordinary course of business. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We do not believe the ultimate liability, if any, for outstanding proceedings or claims, individually or in the aggregate, in excess of amounts already provided, will have a material adverse effect on our consolidated financial condition, results of operations, or cash flows. It is reasonably possible that an adverse determination might have an impact on a particular period. While we believe our provision for legal contingencies is adequate, the outcome of legal proceedings is difficult to predict, and we may settle legal claims or be subject to judgments for amounts that exceed our estimates.
Related Party Transactions	Related Party Transactions There were no material related party transactions that meet the requirements for disclosure in the periods presented other than those disclosed elsewhere in these notes to the unaudited condensed consolidated financial statements.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards There were no new accounting standards adopted during the six months ended June 30, 2026. Recently Issued Accounting Standards In November 2024, the FASB issued Accounting Standards Update (“ASU”) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which was further clarified in January 2025 through the issuance of ASU 2025-01. These ASUs require new financial statement disclosures to provide disaggregated information for certain types of expenses, including purchases of inventory, employee compensation, depreciation, and amortization in commonly presented expense captions such as cost of goods and services and selling, general, and administrative expenses. The amendments in these ASUs are effective for annual periods beginning after December 15, 2026, with early adoption permitted. The adoption of this guidance will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to the related disclosures. In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which modernizes the accounting for internal-use software costs by removing all references to prescriptive and sequential software development stages. The new standard requires entities to consider whether significant development uncertainty has been resolved before starting to capitalize software costs and aligns disclosure requirements with Accounting Standards Codification (“ASC”) 360, Property, Plant, and Equipment. The ASU is effective for annual and interim reporting periods beginning after December 15, 2027, and can be applied prospectively, retrospectively, or using a modified transition method, with early adoption permitted. The Company is currently evaluating the impacts of this guidance on the consolidated financial statements and related disclosures.

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

+ Details

Segment Information - Additional Information (Details)	6 Months Ended
Segment Information - Additional Information (Details)	Jun. 30, 2026 Segment
Segment Reporting [Abstract]
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	srt:ChiefExecutiveOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	Segment EBITDA is used as the key profitability measure when we set our annual operating plan for each segment, is the metric with which our CODM assesses segment results, and is a key component of our annual variable compensation plans. Segment EBITDA is commonly used as an analytical indicator within the health care industry and is utilized in the evaluation of segment operating performance as it is a profit measure that is generally within the control of the operating segments.
Number of reportable segments	2

Discontinued Operations - Summary of the Significant Non-cash Items and Purchases of Property and Equipment (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities of discontinued operations:
Share-based compensation	$ 23,169	$ 38,483
Gain on sale of discontinued operations	(101,868)
Community Living Business \| Discontinued Operations
Cash flows from operating activities of discontinued operations:
Depreciation and amortization	0	1,329
Share-based compensation	(9,296)	6,501
Gain on sale of discontinued operations	(101,868)	0
Cash flows used in investing activities of discontinued operations:
Purchases of property and equipment	$ 3,085	$ 5,868

Discontinued Operations - Summary of the Reconciles the Gross Proceeds With the Gain on Sale, Net of Tax for the Sale (Details) - Community Living Business $ in Thousands	6 Months Ended
	Jun. 30, 2026 USD ($)
Disposal Group, Including Discontinued Operations [Line Items]
Gross proceeds	$ 835,000
Less: certain post-closing adjustments	12,617
Less: direct costs to sell	13,854
Less: carrying amount of Community Living business	706,661
Gain on sale of discontinued operations	101,868
Less: current and deferred tax impact	72,218
Net gain on sale of discontinued operations	$ 29,650

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Earnings Per Share ("EPS") - Summary of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Numerator:
Net income from continuing operations	$ 86,604	$ 8,541	$ 160,887	$ 17,757
Less: Net loss attributable to noncontrolling interests	(81)	(666)	(238)	(1,198)
Net income from continuing operations attributable to common shareholders	86,685	9,207	161,125	18,955
Net (loss) income from discontinued operations	(2,395)	19,001	71,932	38,795
Net income attributable to common shareholders	$ 84,290	$ 28,208	$ 233,057	$ 57,750
Denominator:
Weighted-average shares outstanding - basic	206,042	201,807	205,381	200,516
Weighted-average shares outstanding - diluted	220,276	216,336	221,191	214,963
Basic income (loss) per share attributable to common shareholders:
Continuing operations	$ 0.42	$ 0.05	$ 0.78	$ 0.09
Discontinued operations	(0.01)	0.09	0.35	0.2
Net income per share	0.41	0.14	1.13	0.29
Diluted income (loss) per share attributable to common shareholders:
Continuing operations	0.39	0.04	0.73	0.09
Discontinued operations	(0.01)	0.09	0.32	0.18
Net income per share	$ 0.38	$ 0.13	$ 1.05	$ 0.27
Stock Options
Denominator:
Weighted-average shares outstanding - diluted	8,947	8,098	9,468	8,167
RSUs
Denominator:
Weighted-average shares outstanding - diluted	5,287	6,431	6,342	6,280
TEUs
Denominator:
Weighted-average shares outstanding - diluted	0	0	0	0

Significant Accounting Policies

6 Months Ended

Jun. 30, 2026

Accounting Policies [Abstract]

Significant Accounting Policies

1. Significant Accounting Policies

Description of Business

BrightSpring Health Services, Inc. and its subsidiaries (“BrightSpring”, the “Company”, “we,” “us,” or “our”) is a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to medically complex patients. Our platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially-insured populations.

On December 7, 2017, affiliates of Kohlberg Kravis Roberts & Co. L.P. (“KKR Stockholder”) and Walgreens Boots Alliance, Inc. (“WBA”) purchased PharMerica Corporation (“PharMerica”) and on March 5, 2019, expanded with the acquisition of BrightSpring Health Holdings Corp. The surviving entity was renamed BrightSpring Health Services, Inc. WBA sold their remaining ownership interests in the Company in 2025 through open market transactions and is no longer considered a related party of the Company. As a result of the registered secondary public offerings in 2025, the Company no longer qualifies as a “controlled company” under the Nasdaq Stock Market LLC listing standards.

On January 17, 2025, the Company entered into a purchase agreement to divest its community living services, home and community based waiver programs, and intermediate care facilities (the “Community Living business”). The transaction closed on March 30, 2026.

In March and June 2026, KKR Stockholder and certain management selling stockholders completed additional registered secondary public offerings of 20,000,000 and 14,999,771 shares of the Company’s common stock, respectively (collectively, the “2026 Secondary Offerings”). The Company did not sell any shares of common stock that were offered in the 2026 Secondary Offerings. The Company did not receive any proceeds from the 2026 Secondary Offerings, other than proceeds received in connection with the cash exercise of stock options by the management selling stockholders in connection with the 2026 Secondary Offerings. In connection with the March and June 2026 secondary public offerings, the Company concurrently purchased from the underwriter 1,464,807 and 1,026,465 shares of common stock, respectively. The price per share paid by the Company with respect to the concurrent share repurchases was equal to the price at which the underwriter purchased the shares from the selling stockholders in the 2026 Secondary Offerings. The par value of the shares repurchased and the amount paid to repurchase the shares in excess of the par value were recorded as common stock and retained earnings, respectively, in the unaudited condensed consolidated balance sheets.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of BrightSpring Health Services, Inc. and its subsidiaries. The Company consolidates its majority-owned and controlled entities, including variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

We record a noncontrolling interest for the allocable portion of income or loss and comprehensive income or loss to which the noncontrolling interest holders are entitled based upon their ownership share of the affiliate. The Company determined noncontrolling interests for certain of these VIEs to be redeemable noncontrolling interests, which are presented in the unaudited condensed consolidated balance sheets as redeemable noncontrolling interests.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations, and our cash flows in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year.

As discussed in Note 2, the Community Living business met the criteria to be reported as discontinued operations and held for sale during the first fiscal quarter of 2025. Therefore, the Company has reported the historical results of the Community Living business, including the results of operations and cash flows as discontinued operations for all periods presented herein, and related assets and liabilities, as held for sale as of December 31, 2025. Unless otherwise noted, all activities and amounts reported in the accompanying notes to the unaudited condensed consolidated financial statements relate to the continuing operations of the Company and exclude activities and amounts related to the Community Living business.

This report should be read in conjunction with our consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, which includes information and disclosures not included herein. Certain

information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by the rules and regulations of the Securities and Exchange Commission.

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts and related disclosures. We rely on historical experience and on various other assumptions that we believe to be reasonable under the circumstances to make judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates are involved in the valuation of accounts receivable, inventory, intangible assets, derivatives, contingent consideration, taxes, insurance reserves, share-based compensation, and goodwill. Actual amounts may differ from these estimates.

Commitments and Contingencies

The Company is party to various legal and/or administrative proceedings arising out of the operation of our programs and arising in the ordinary course of business. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We do not believe the ultimate liability, if any, for outstanding proceedings or claims, individually or in the aggregate, in excess of amounts already provided, will have a material adverse effect on our consolidated financial condition, results of operations, or cash flows. It is reasonably possible that an adverse determination might have an impact on a particular period. While we believe our provision for legal contingencies is adequate, the outcome of legal proceedings is difficult to predict, and we may settle legal claims or be subject to judgments for amounts that exceed our estimates.

Related Party Transactions

There were no material related party transactions that meet the requirements for disclosure in the periods presented other than those disclosed elsewhere in these notes to the unaudited condensed consolidated financial statements.

Recently Adopted Accounting Standards

There were no new accounting standards adopted during the six months ended June 30, 2026.

Recently Issued Accounting Standards

In November 2024, the FASB issued Accounting Standards Update (“ASU”) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which was further clarified in January 2025 through the issuance of ASU 2025-01. These ASUs require new financial statement disclosures to provide disaggregated information for certain types of expenses, including purchases of inventory, employee compensation, depreciation, and amortization in commonly presented expense captions such as cost of goods and services and selling, general, and administrative expenses. The amendments in these ASUs are effective for annual periods beginning after December 15, 2026, with early adoption permitted. The adoption of this guidance will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to the related disclosures.

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which modernizes the accounting for internal-use software costs by removing all references to prescriptive and sequential software development stages. The new standard requires entities to consider whether significant development uncertainty has been resolved before starting to capitalize software costs and aligns disclosure requirements with Accounting Standards Codification (“ASC”) 360, Property, Plant, and Equipment. The ASU is effective for annual and interim reporting periods beginning after December 15, 2027, and can be applied prospectively, retrospectively, or using a modified transition method, with early adoption permitted. The Company is currently evaluating the impacts of this guidance on the consolidated financial statements and related disclosures.

Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands

Total

Common Stock

Additional Paid-In Capital

(Accumulated Deficit) Retained Earnings

Accumulated Other Comprehensive (Loss) Income

Noncontrolling Interest

Balance at Dec. 31, 2024

$ 1,647,855

$ 1,742

$ 1,866,850

$ (222,155)

$ 1,418

Balance, shares at Dec. 31, 2024

174,245,990

Net income (loss)

^[1]

57,467

57,750

$ (283)

Other comprehensive income (loss) , net of tax

(5,748)

Share-based compensation

38,483

Exercise of stock options

9,062

$ 14

9,048

Exercise of stock options, shares

1,320,135

Issuance of common stock for settlement of RSUs

$ 17

(17)

Issuance of common stock for settlement of RSUs, shares

1,701,546

Tax effect of net share settlement of equity awards

(4,512)

$ (2)

(4,510)

Tax effect of net share settlement of equity awards, shares

(212,344)

Balance at Jun. 30, 2025

1,742,607

$ 1,771

1,909,854

(164,405)

(4,330)

(283)

Balance, shares at Jun. 30, 2025

177,055,327

Balance at Mar. 31, 2025

1,687,244

$ 1,752

1,880,099

(192,613)

(1,869)

(125)

Balance, shares at Mar. 31, 2025

175,183,434

Net income (loss)

^[2]

28,050

28,208

(158)

Other comprehensive income (loss) , net of tax

(2,461)

Share-based compensation

22,802

Exercise of stock options

8,717

$ 14

8,703

Exercise of stock options, shares

1,283,882

Issuance of common stock for settlement of RSUs

$ 6

(6)

Issuance of common stock for settlement of RSUs, shares

649,010

Tax effect of net share settlement of equity awards

(1,745)

$ (1)

(1,744)

Tax effect of net share settlement of equity awards, shares

(60,999)

Balance at Jun. 30, 2025

1,742,607

$ 1,771

1,909,854

(164,405)

(4,330)

(283)

Balance, shares at Jun. 30, 2025

177,055,327

Balance at Dec. 31, 2025

1,875,139

$ 1,921

1,954,482

(74,647)

(6,691)

Balance, shares at Dec. 31, 2025

192,124,125

Net income (loss)

^[1]

233,064

233,057

Other comprehensive income (loss) , net of tax

10,876

Share-based compensation

23,169

Exercise of stock options

32,415

$ 39

32,376

Exercise of stock options, shares

3,940,023

Issuance of common stock for settlement of RSUs

$ 16

(16)

Issuance of common stock for settlement of RSUs, shares

1,572,874

Tax effect of net share settlement of equity awards

(6,607)

$ (2)

(6,605)

Tax effect of net share settlement of equity awards, shares

(162,405)

Conversion of tangible equity units into common stock

$ 25

(25)

Conversion of tangible equity units into common stock, shares

2,526,146

Share repurchase

(120,000)

$ (24)

(119,976)

Share repurchase, shares

(2,491,272)

Other

729

742

(13)

Balance at Jun. 30, 2026

2,048,785

$ 1,975

2,004,123

38,434

4,185

Balance, shares at Jun. 30, 2026

197,509,491

Balance at Mar. 31, 2026

1,979,381

$ 1,932

1,964,516

14,135

(1,265)

Balance, shares at Mar. 31, 2026

193,209,722

Net income (loss)

^[2]

84,295

84,290

Other comprehensive income (loss) , net of tax

5,450

Share-based compensation

19,493

Exercise of stock options

20,323

$ 25

20,298

Exercise of stock options, shares

2,562,315

Issuance of common stock for settlement of RSUs

$ 3

(3)

Issuance of common stock for settlement of RSUs, shares

256,489

Tax effect of net share settlement of equity awards

(899)

$ (1)

(898)

Tax effect of net share settlement of equity awards, shares

(18,716)

Conversion of tangible equity units into common stock

$ 25

(25)

Conversion of tangible equity units into common stock, shares

2,526,146

Share repurchase

(60,000)

$ (9)

(59,991)

Share repurchase, shares

(1,026,465)

Other

742

Balance at Jun. 30, 2026

$ 2,048,785

$ 1,975

$ 2,004,123

$ 38,434

$ 4,185

$ 68

Balance, shares at Jun. 30, 2026

197,509,491

[1]	Net income (loss) to the Company for the six months ended June 30, 2026 and 2025 excludes ($245) and $(915), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.
[2]	Net income (loss) to the Company for the three months ended June 30, 2026 and 2025 excludes ($86) and $(508), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Statement of Comprehensive Income [Abstract]
Income tax effects of net change in fair value	$ (1,914)	$ (201)	$ (3,849)	$ (234)
Income tax effects of amounts reclassified to earnings	$ 108	$ 1,080	$ 252	$ 2,167

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Property and equipment, net of accumulated depreciation	$ 438,963	$ 404,878
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	1,500,000,000	1,500,000,000
Common Stock, Shares, Issued	197,509,491	192,124,125
Common Stock, shares outstanding	197,509,491	192,124,125
Preferred Stock , par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	250,000,000	250,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2026

Income Tax Disclosure [Abstract]

Schedule of Reconciliation of Effective Tax Rate

A reconciliation of the Company’s effective tax rate is as follows:


	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2026			2025			2026			2025
Estimated annual effective tax rate before discrete items		25.4	%		27.1	%		25.4	%		26.4	%
Discrete items recognized		(18.0	)%		(14.4	)%		(16.6	)%		(21.1	)%
Effective tax rate recognized in the statements of operations		7.4	%		12.7	%		8.8	%		5.3	%

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Changes to Goodwill, by Reportable Segment

A summary of changes to goodwill, by reportable segment, is as follows (in thousands):


	Goodwill
	Pharmacy Solutions		Provider Services			Total
Goodwill at January 1, 2026*	$	841,052	$	1,704,621		$	2,545,673
Measurement period adjustments		—		(10,289	)		(10,289	)
Foreign currency adjustments		—		(140	)		(140	)
Goodwill at June 30, 2026*	$	841,052	$	1,694,192		$	2,535,244

* For the periods presented, the carrying amount of goodwill is presented net of accumulated impairment losses of $40.9 million, which were incurred in fiscal year 2022.

Schedule of Intangible Assets

Intangible assets are as follows (in thousands):


	June 30, 2026						December 31, 2025
	Gross		Accumulated Amortization		Net Carrying Value		Gross		Accumulated Amortization		Net Carrying Value		Life (Years)
Customer relationships	$	501,510	$	381,851	$	119,659	$	502,160	$	356,146	$	146,014	5-20
Trade names		318,768		165,644		153,124		318,768		154,601		164,167	2-20
Licenses		67,120		21,011		46,109		67,395		18,886		48,509	10-20
Doctor/payor network		3,300		2,922		378		5,650		4,987		663	5-8
Covenants not to compete		3,834		2,438		1,396		6,654		4,717		1,937	2-7
Other intangible assets		10,940		8,707		2,233		10,940		7,925		3,015	5-7
Total definite-lived assets	$	905,472	$	582,573	$	322,899	$	911,567	$	547,262	$	364,305
Licenses		191,525		—		191,525		193,250		—		193,250	Indefinite
Total intangible assets	$	1,096,997	$	582,573	$	514,424	$	1,104,817	$	547,262	$	557,555

- Definition

Tabular disclosure of goodwill.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Income Taxes

6 Months Ended

Jun. 30, 2026

Income Tax Disclosure [Abstract]

Income Taxes

8. Income Taxes

The provision for income taxes is attributable to U.S federal, state, and foreign income taxes. The Company’s effective tax rate used for interim periods is based on an estimated annual effective tax rate and includes the tax effect of items required to be recorded discretely in the interim periods in which those items occur.

A reconciliation of the Company’s effective tax rate is as follows:


	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2026			2025			2026			2025
Estimated annual effective tax rate before discrete items		25.4	%		27.1	%		25.4	%		26.4	%
Discrete items recognized		(18.0	)%		(14.4	)%		(16.6	)%		(21.1	)%
Effective tax rate recognized in the statements of operations		7.4	%		12.7	%		8.8	%		5.3	%

During the three and six months ended June 30, 2026 and 2025, the Company’s effective tax rates were lower than the U.S. federal income tax rate, primarily due to excess tax benefits recognized on share-based compensation awards. Excess tax benefits totaled $16.9 million and $29.3 million for the three and six months ended June 30, 2026, respectively, compared to $1.4 million and $3.7 million for the three and six months ended June 30, 2025. These benefits are recognized as discrete tax items in the periods in which awards vest or are exercised and can vary significantly based on the Company’s stock price and employee activity. The favorable impact of these benefits was partially offset by permanent tax adjustments related to compensation that is nondeductible under Section 162(m) of the Internal Revenue Code.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Debt and Derivatives (Tables)

6 Months Ended

Jun. 30, 2026

Debt Disclosure [Abstract]

Schedule of Total Outstanding Debt

The table below summarizes the total outstanding debt of the Company (in thousands):


	June 30, 2026					December 31, 2025
	Rate			Amount		Rate			Amount
First Lien Incremental Term Loan Tranche B-6 - payable to lenders at SOFR plus applicable margin		5.62	%	$	2,214,872		—		$	—
First Lien Incremental Term Loan Tranche B-5 - payable to lenders at SOFR plus applicable margin		—			—		6.22	%		2,521,255
Revolving Credit Loans - payable to lenders at SOFR plus applicable margin		5.62	%		—		6.47	%		—
Swingline/Base Rate - payable to lenders at ABR plus applicable margin		7.75	%		—		8.50	%		—
Amortizing Notes (1)					19,278					31,360
Notes payable and other					15,103					17,129
Total debt					2,249,253					2,569,744
Less: debt issuance costs, net					58,493					62,200
Total debt, net of debt issuance costs					2,190,760					2,507,544
Less: current portion of long-term debt					41,445					52,340
Total long-term debt, net of current portion				$	2,149,315				$	2,455,204

See Note 7 for discussion of Amortizing Notes

Summary of Carrying Value and Estimated Fair Values of Debt Obligations

The following table presents the carrying value and estimated fair values of the Company’s debt obligations as of June 30, 2026 (in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of June 30, 2026		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Term Loan	$	2,214,872	$	—	$	2,214,872	$	—
Amortizing Notes		19,278		—		19,302		—
Total debt instruments	$	2,234,150	$	—	$	2,234,174	$	—

Schedule of Interest Rate Swap with Notional Value

The following table summarizes our interest rate swaps designated as cash flow hedges (in millions):


	Notional Amount as of
Financial Institution	June 30, 2026		December 31, 2025		Effective Dates	Fixed Rates
Credit Agricole Corporate and Investment Bank	$	500	$	500	1-year period ending September 30, 2026		3.72500	%
Mizuho Capital Markets		500		500	1-year period ending September 30, 2026		3.61121	%
Credit Agricole Corporate and Investment Bank		250		250	3-year period ending September 30, 2028		3.33150	%
Morgan Stanley		250		250	3-year period ending September 30, 2028		3.17700	%
Existing contracts	$	1,500	$	1,500

Mizuho Capital Markets	$	500	$	500	2-year period ending September 30, 2028		3.20220	%
Forward starting contracts (1)	$	500	$	500

(1)

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

+ Details

Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2026

Jun. 30, 2025

Jun. 30, 2026

Jun. 30, 2025

Statement of Comprehensive Income [Abstract]

Net income

$ 84,209

$ 27,542

$ 232,819

$ 56,552

Other comprehensive income (loss), net of tax:

Foreign currency translation adjustments

(114)

246

(206)

208

Cash flow hedges:

Net change in fair value, net of tax

^[1]

5,896

614

11,858

722

Amounts reclassified to earnings, net of tax

^[2]

(332)

(3,321)

(776)

(6,678)

Total other comprehensive income (loss), net of tax

5,450

(2,461)

10,876

(5,748)

Total comprehensive income

89,659

25,081

243,695

50,804

Comprehensive loss attributable to redeemable noncontrolling interests

(86)

(508)

(245)

(915)

Comprehensive income (loss) attributable to noncontrolling interest

(158)

(283)

Comprehensive income attributable to BrightSpring Health Services, Inc. and subsidiaries

$ 89,740

$ 25,747

$ 243,933

$ 52,002

[1]	The income tax effects of the net change in fair value were $(1,914) and $(3,849) for the three and six months ended June 30, 2026, respectively, and $(201) and $(234) for the three and six months ended June 30, 2025, respectively.
[2]	The income tax effects of amounts reclassified to earnings were $108 and $252 for the three and six months ended June 30, 2026, respectively, and $1,080 and $2,167 for the three and six months ended June 30, 2025, respectively.

Discontinued Operations - Additional Information (Details) - USD ($) $ in Thousands		6 Months Ended
	Mar. 30, 2026	Jun. 30, 2026	Jan. 17, 2025
Disposal Group, Including Discontinued Operations [Line Items]
Definitive agreement for cash proceeds		$ 810,908
Community Living Business
Disposal Group, Including Discontinued Operations [Line Items]
Pre-tax gain on sale		$ 101,868
Community Living Business \| Discontinued Operations
Disposal Group, Including Discontinued Operations [Line Items]
Cash receivable for the disposal including discontinued operation			$ 835,000
Definitive agreement for cash proceeds	$ 810,900
Pre-tax gain on sale	$ 101,900

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Detail of Certain Balance Sheet Accounts - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Disclosure Text Block Supplement [Abstract]
Insurance recoveries	$ 40,760	$ 7,251
Interest rate swaps	14,167	1,181
Other investments	7,544	7,481
Cloud computing	6,863	6,017
Deposits	5,816	5,722
Deferred compensation	5,022	4,702
Notes receivable	1,940	4,012
Other assets	3,122	3,346
Total other assets	$ 85,234	$ 39,712

Segment Information

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Segment Information

11. Segment Information

The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer, who evaluates the performance of our segments and allocates resources based on segment EBITDA. Segment EBITDA is used as the key profitability measure when we set our annual operating plan for each segment, is the metric with which our CODM assesses segment results, and is a key component of our annual variable compensation plans. Segment EBITDA is commonly used as an analytical indicator within the health care industry and is utilized in the evaluation of segment operating performance as it is a profit measure that is generally within the control of the operating segments.

For all segments, the CODM uses segment EBITDA in the annual budgeting and monthly forecasting process. The CODM considers actual-to budget and actual-to current forecast variances for segment EBITDA on a monthly basis for evaluating performance of each segment and making decisions about allocating capital and other resources to each segment.

Segment amounts exclude certain expenses not specifically identifiable to the segments for functions performed in a centralized manner, which include accounting, finance, human resources, legal, information technology, corporate office support, and overall corporate management. Segment assets and capital expenditures are not provided to the Company’s CODM and, therefore, are not disclosed.


	For the Three Months Ended June 30, 2026
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	3,407,173	$	—	$	3,407,173
Services revenue		—		465,967		465,967
Cost of drugs		2,916,899		—		2,916,899
Cost of services		—		271,402		271,402
Other direct costs (1)		192,093		—		192,093
Segment selling, general, and administrative expenses (2)		143,612		128,515		272,127
Segment depreciation and amortization expense (3)		25,480		8,811		34,291
Segment EBITDA	$	180,049	$	74,861	$	254,910


	For the Three Months Ended June 30, 2025
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	2,790,101	$	—	$	2,790,101
Services revenue		—		357,597		357,597
Cost of drugs		2,377,477		—		2,377,477
Cost of services		—		216,444		216,444
Other direct costs (1)		178,925		—		178,925
Segment selling, general, and administrative expenses (2)		136,040		91,871		227,911
Segment depreciation and amortization expense (3)		27,033		7,174		34,207
Segment EBITDA	$	124,692	$	56,456	$	181,148


	For the Six Months Ended June 30, 2026
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	6,578,522	$	—	$	6,578,522
Services revenue		—		908,339		908,339
Cost of drugs		5,589,692		—		5,589,692
Cost of services		—		532,326		532,326
Other direct costs (1)		389,875		—		389,875
Segment selling, general, and administrative expenses (2)		300,646		250,937		551,583
Segment depreciation and amortization expense (3)		50,808		15,765		66,573
Segment EBITDA	$	349,117	$	140,841	$	489,958


	For the Six Months Ended June 30, 2025
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	5,322,272	$	—	$	5,322,272
Services revenue		—		703,555		703,555
Cost of drugs		4,525,053		—		4,525,053
Cost of services		—		427,989		427,989
Other direct costs (1)		359,564		—		359,564
Segment selling, general, and administrative expenses (2)		251,778		181,973		433,751
Segment depreciation and amortization expense (3)		54,541		13,943		68,484
Segment EBITDA	$	240,418	$	107,536	$	347,954

(1)

Other direct costs primarily includes direct labor costs, delivery costs, insurance, and depreciation and amortization expense that relates to revenue-generating assets.

(2)

(3)

Total segment depreciation and amortization expense is presented in other direct costs, costs of services, and segment general and administrative expenses, based on the associated asset.


	For the Three Months Ended				For the Six Months Ended
	June 30,				June 30,
	2026		2025		2026		2025
Reconciliation of income:
Total Segment EBITDA	$	254,910	$	181,148	$	489,958	$	347,954
Segment depreciation and amortization		34,291		34,207		66,573		68,484
Expenses not allocated at segment level:
Selling, general, and administrative expenses		83,096		90,752		157,601		165,987
Depreciation and amortization		7,132		7,632		13,944		14,187
Interest expense, net		36,879		38,778		75,494		80,541
Income tax expense		6,908		1,238		15,459		998
Net income from continuing operations	$	86,604	$	8,541	$	160,887	$	17,757

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details